{"content":"<li class=\"n-box-item date-title\" data-end=\"1551934799\" data-start=\"1551848400\" data-txt=\"Monday, December 23, 2019\">Wednesday, March  6, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3440540\" data-ts=\"1551911583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440540-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color=\"green\">+17.9%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color=\"green\">+9.7%</font>. <a href='https://seekingalpha.com/symbol/GWRE' title='Guidewire Software, Inc.'>GWRE</a> <font color=\"green\">+8.1%</font>. <a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a> <font color=\"green\">+7.0%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color=\"green\">+7.0%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a> <font color=\"red\">-10.8%</font>. <a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a> <font color=\"red\">-7.1%</font>. <a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"red\">-3.6%</font>. <a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color=\"red\">-3.4%</font>. <a href='https://seekingalpha.com/symbol/ARTX' title='Arotech Corporation'>ARTX</a> <font color=\"red\">-3.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440540\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ALT $HIIQ $GWRE - After Hours Gainers / Losers https://seekingalpha.com/news/3440540-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440540-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440524\" data-ts=\"1551910405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCRD\" target=\"_blank\">TCRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440524-thl-creditminus-1_3-after-dividend-cut-q4-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">THL Credit -1.3% after dividend cut, Q4 miss</a></h4><ul><li>THL Credit (NASDAQ:<a href='https://seekingalpha.com/symbol/TCRD' title='THL Credit'>TCRD</a>) reports<a href=\"https://seekingalpha.com/pr/17436071-thl-credit-reports-fourth-quarter-2018-financial-results-announces-adjustment-quarterly\" target=\"_blank\"> Q4 net investment income</a> of 23 cents per share, missing the average analyst estimate of 25 cents, and down from 27 cents in the year-earlier quarter.</li><li>Adjusts dividend to reflect the BDC's current earnings potential; declares dividend of 21 cents per share vs. prior 27 cents.</li><li>THL <font color=\"red\">falls 1.3% </font>in after-hours trading.</li><li>Waives additional incentive fees to the extent earned through the end of 2019, as well as to lower base management fee to more closely align with what it believes appropriate for a first lien floating rate portfolio.</li><li>Will implement a new $15M 10b-1 stock repurchase plan and plans to buy back stock at levels accretive to shareholders with proceeds from exits of additional control equity positions this year.</li><li><a href=\"https://www.globenewswire.com/Tracker?data=bm9Pno4G5Ui5sCE0hSxTEs3b2slNaod6gXAwMfAiIWuM5L4yV5GGLp2_FYRfDQcUkRUFE-XM1NduSu3viPyDIiBt3JgtxNemTyW51FCrF0g=\" target=\"_blank\">Conference call</a> on March 7 at 10:30  AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440449-thl-credit-misses-0_02-misses-total-investment-income\" target=\"_blank\">THL Credit misses by $0.02, misses on total investment income</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440524\" data-linked=\"THL Credit -1.3% after dividend cut, Q4 miss\" data-tweet=\"$TCRD - THL Credit -1.3% after dividend cut, Q4 miss https://seekingalpha.com/news/3440524-thl-creditminus-1_3-after-dividend-cut-q4-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3440524-thl-creditminus-1_3-after-dividend-cut-q4-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440510\" data-ts=\"1551909692\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFNX\" target=\"_blank\">PFNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440510-pfenex-up-6-after-hours-on-advancement-of-pneumococcal-vaccine-in-india\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pfenex up 6% after hours on advancement of pneumococcal vaccine in India</a></h4><ul><li>Pfenex (NYSEMKT:<a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex'>PFNX</a>) is up <font color=\"green\">6%</font> after hours in response to <a href=\"https://seekingalpha.com/pr/17436042-pfenex-licensee-successfully-completes-phase-3-study-enters-registration-pneumosil\" target=\"_blank\">successful results</a> from an India-based Phase 3 clinical trial evaluating Pneumosil, a 10-valent pneumococcal conjugate vaccine, conducted by Serum Institute of India Private Limited. All primary and secondary endpoints were met.</li><li>The vaccine contains a recombinant carrier protein, CRM197, produced by Serum Institute under a license to the <em>Pf</em>ēnex Expression Technology. </li><li>Serum Institute has received an export license for the product.</li><li>Pfenex is eligible to receive annual fees, milestones and tiered low single-digit royalties on net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440510\" data-linked=\"Pfenex up 6% after hours on advancement of pneumococcal vaccine in India\" data-tweet=\"$PFNX - Pfenex up 6% after hours on advancement of pneumococcal vaccine in India https://seekingalpha.com/news/3440510-pfenex-up-6-after-hours-on-advancement-of-pneumococcal-vaccine-in-india?source=tweet\" data-url=\"https://seekingalpha.com/news/3440510-pfenex-up-6-after-hours-on-advancement-of-pneumococcal-vaccine-in-india\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440506\" data-ts=\"1551909219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMTL\" target=\"_blank\">CMTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440506-comtechplus-7-after-revenue-beat-and-raise-in-fiscal-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comtech +7% after revenue beat-and-raise in fiscal Q2</a></h4><ul>   <li>Comtech Telecommunications (NASDAQ:<a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a>) is <font color=\"green\">up 7%</font> postmarket after it beat expectations on top and bottom lines in its fiscal Q2 results, and boosted revenue and EBITDA guidance for the full year.</li>    <li>Revenues rose nearly 23% to $164.1M. Bookings for the quarter hit $123.3M, with book-to-bill at 0.75.</li>    <li>Backlog as of Jan. 31 was $586.4M, not including parts of multi-year contracts that haven't yet been funded.</li>    <li>And EBITDA rose to $23.2M, up 60%.</li>    <li>The company raised revenue expectations for 2019 to $645M-$660M, from a previous $625M-$640M, and boosted EBITDA guidance to $85M-$89M.</li>    <li>It also lowered its expected GAAP EPS range to $0.86-$0.98 from $0.95-$1.08, due to expenses tied to long-term efficiency gains, higher amortization of intangibles from the Solacom acquisition, and higher interest and acquisition plan expenses.</li>    <li><a href=\"https://edge.media-server.com/m6/p/s4ydvgoa\" target=\"_blank\">Conference call</a> to come tomorrow at 8:30 a.m. ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440484-comtech-telecommunications-beats-0_23-beats-revenue\" target=\"_blank\">Comtech Telecommunications beats by $0.23, beats on revenue</a> (Mar. 06 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17436119-comtech-telecommunications-corp-announces-results-fiscal-2019-second-quarter-updates-fiscal\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3440506\" data-linked=\"Comtech +7% after revenue beat-and-raise in fiscal Q2\" data-tweet=\"$CMTL - Comtech +7% after revenue beat-and-raise in fiscal Q2 https://seekingalpha.com/news/3440506-comtechplus-7-after-revenue-beat-and-raise-in-fiscal-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3440506-comtechplus-7-after-revenue-beat-and-raise-in-fiscal-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440503\" data-ts=\"1551908985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APVO\" target=\"_blank\">APVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440503-aptevo-readies-equity-offering-shares-down-12-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptevo readies equity offering; shares down 12% after hours</a></h4><ul><li>Aptevo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a>) <a href=\"https://seekingalpha.com/pr/17436162-aptevo-announces-proposed-public-offering-common-stock-warrants\" target=\"_blank\">commences </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down <font color=\"red\">12%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440503\" data-linked=\"Aptevo readies equity offering; shares down 12% after hours\" data-tweet=\"$APVO - Aptevo readies equity offering; shares down 12% after hours https://seekingalpha.com/news/3440503-aptevo-readies-equity-offering-shares-down-12-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3440503-aptevo-readies-equity-offering-shares-down-12-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440492\" data-ts=\"1551908675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNA\" target=\"_blank\">CDNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440492-caredx-q4-q4-top-line-up-88\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CareDx Q4 Q4 top line up 88%</a></h4><ul><li>CareDx (NASDAQ:<a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a>) <a href=\"https://seekingalpha.com/pr/17436000-caredx-reports-fourth-quarter-fy-2018-results\" target=\"_blank\">Q4 results</a> ($M): Revenue: 23.5 (+88.0%); testing services: 18.9 (+119.8%).</li><li>Net loss: (3.8) (+88.0%); non-GAAP net income: 0.3 (+113.2%); loss/share: (0.09) (+92.0%); non-GAAP EPS: 0.01 (+111.1%).</li><li>4,575 AlloSure test provided to ~3,400 patients.</li><li><strong>2019 guidance</strong>: Revenue: $105M - 107M.</li><li>Shares are down <font color=\"red\">2%</font> after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440428-caredx-beats-0_10-beats-revenue\" target=\"_blank\">CareDx beats by $0.10, beats on revenue</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440492\" data-linked=\"CareDx Q4 Q4 top line up 88%\" data-tweet=\"$CDNA - CareDx Q4 Q4 top line up 88% https://seekingalpha.com/news/3440492-caredx-q4-q4-top-line-up-88?source=tweet\" data-url=\"https://seekingalpha.com/news/3440492-caredx-q4-q4-top-line-up-88\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440501\" data-ts=\"1551908340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YEXT\" target=\"_blank\">YEXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440501-yextplus-1_6-after-q4-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yext +1.6% after Q4 beats</a></h4><ul><li>Yext (NYSE:<a href='https://seekingalpha.com/symbol/YEXT' title='Yext, Inc.'>YEXT</a>) <font color=\"green\">gains 1.6%</font> after it reports Q4 beats with a 33% Y/Y revenue growth. In-line Q1 guidance has revenue from $66M to $67M (consensus: $67.04M) and EPS of -$0.11 to -$0.09 (consensus: -$0.10).</li><li>FY20 outlook has in-line revenue of $295M to $300M (consensus: $297.61M) and downside EPS of -$0.44 to -$0.40 (consensus: -$0.38).</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://investors.yext.com/\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17436110-yext-inc-announces-fourth-quarter-full-year-fiscal-2019-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440465-yext-beats-0_06-beats-revenue\" target=\"_blank\">Yext beats by $0.06, beats on revenue</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440501\" data-linked=\"Yext +1.6% after Q4 beats\" data-tweet=\"$YEXT - Yext +1.6% after Q4 beats https://seekingalpha.com/news/3440501-yextplus-1_6-after-q4-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3440501-yextplus-1_6-after-q4-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440496\" data-ts=\"1551908179\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440496-allergans-rapastinel-flunks-late-stage-mdd-studies-shares-down-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan&#39;s rapastinel flunks late-stage MDD studies; shares down 5% after hours</a></h4><ul><li>Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) is down <font color=\"red\">5%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17436115-allergan-announces-phase-3-results-rapastinel-adjunctive-treatment-major-depressive-disorder\" target=\"_blank\">announcement </a>that interim analyses of three Phase 3 clinical trials evaluating rapastinel for the treatment of major depressive disorder &#40;MDD&#41; revealed that it failed to sufficiently separate from placebo and, therefore, is unlikely to meet the primary and secondary endpoints.</li><li>The company says it will decided on what to do with the programs later this year after assessing the monotherapy data and suicidality in MDD study.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440496\" data-linked=\"Allergan&#39;s rapastinel flunks late-stage MDD studies; shares down 5% after hours\" data-tweet=\"$AGN - Allergan&#39;s rapastinel flunks late-stage MDD studies; shares down 5% after hours https://seekingalpha.com/news/3440496-allergans-rapastinel-flunks-late-stage-mdd-studies-shares-down-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3440496-allergans-rapastinel-flunks-late-stage-mdd-studies-shares-down-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440489\" data-ts=\"1551907708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWRE\" target=\"_blank\">GWRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440489-guidewireplus-8_7-on-q2-beats-upside-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guidewire +8.7% on Q2 beats, upside outlook</a></h4><ul><li>Guidewire Software (NYSE:<a href='https://seekingalpha.com/symbol/GWRE' title='Guidewire Software, Inc.'>GWRE</a>) <font color=\"green\">gains 8.7%</font> after Q2 beats with upside Q3 guidance that has revenue of $152.5M to $156.5M (consensus: $148.58M) and EPS of $0.05 to $0.09 (consensus: $0.05).</li><li>Raised FY19 outlook has revenue of $725M to $732M (consensus: $728.72M; was: $722M to $732M) and EPS from $1.35 to $1.41 (consensus: $1.30; was: $1.24 to $1.34).</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"http://ir.guidewire.com/phoenix.zhtml?c=248177&amp;p=irol-IRHome\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17436093-guidewire-software-announces-second-quarter-fiscal-2019-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440469-guidewire-software-beats-0_15-beats-revenue\" target=\"_blank\">Guidewire Software beats by $0.15, beats on revenue</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440489\" data-linked=\"Guidewire +8.7% on Q2 beats, upside outlook\" data-tweet=\"$GWRE - Guidewire +8.7% on Q2 beats, upside outlook https://seekingalpha.com/news/3440489-guidewireplus-8_7-on-q2-beats-upside-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3440489-guidewireplus-8_7-on-q2-beats-upside-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440487\" data-ts=\"1551907648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440487-health-insurance-innovations-q4-earnings-up-41-shares-up-11-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations Q4 earnings up 41%; shares up 11% after hours</a></h4><ul><li>Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a>) <a href=\"https://seekingalpha.com/pr/17436012-health-insurance-innovations-inc-reports-strong-fourth-quarter-fiscal-2018-results-expands\" target=\"_blank\">Q4 results</a> ($M): Revenues: 131.9 (+89.8%).</li><li>Net income: 5.4 (+40.7%); non-GAAP net income: 15.8 (+159.0%); EPS: 0.40 (+33.3%); non-GAAP EPS: 0.98 (+164.9%); non-GAAP EBITDA: 21.6 (+105.7%).</li><li>Cash flow ops (full year): 21.8 (-51.8%).</li><li><strong>2019 guidance</strong>: Revenue: $430M - 440M; non-GAAP EBITDA: $72M - 77M; non-GAAP EPS: $3.20 - 3.35.</li><li>Shares are up <font color=\"green\">11%</font> after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440453-health-insurance-innovations-beats-0_21-beats-revenue\" target=\"_blank\">Health Insurance Innovations beats by $0.21, beats on revenue</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440487\" data-linked=\"Health Insurance Innovations Q4 earnings up 41%; shares up 11% after hours\" data-tweet=\"$HIIQ - Health Insurance Innovations Q4 earnings up 41%; shares up 11% after hours https://seekingalpha.com/news/3440487-health-insurance-innovations-q4-earnings-up-41-shares-up-11-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3440487-health-insurance-innovations-q4-earnings-up-41-shares-up-11-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440485\" data-ts=\"1551907381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLR\" target=\"_blank\">MLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440485-miller-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Miller reports Q4 results</a></h4><ul><li>Miller (NYSE:<a href='https://seekingalpha.com/symbol/MLR' title='Miller Industries Inc.'>MLR</a>): Q4 GAAP EPS of $0.95.</li><li>Revenue of $179.97M (+12.7% Y/Y)</li><li>Shares <font color=\"green\">+2.26%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17436107-miller-industries-reports-2018-fourth-quarter-full-year-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440485\" data-linked=\"Miller reports Q4 results\" data-tweet=\"$MLR - Miller reports Q4 results https://seekingalpha.com/news/3440485-miller-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3440485-miller-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440457\" data-ts=\"1551906835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGR\" target=\"_blank\">AVGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440457-avinger-misses-0_02-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avinger misses by $0.02, misses on revenue</a></h4><ul><li>Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a>): Q4 GAAP EPS of -$0.31 <span style=\"color:red\">misses by $0.02</span>.</li><li>Revenue of $2.03M (+6.3% Y/Y) <font color=\"red\">misses by $0.51M</font>.</li><li>Shares <font color=\"green\">+6.6%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17436056-avinger-provides-fourth-quarter-full-year-2018-shareholder-update\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440457\" data-linked=\"Avinger misses by $0.02, misses on revenue\" data-tweet=\"$AVGR - Avinger misses by $0.02, misses on revenue https://seekingalpha.com/news/3440457-avinger-misses-0_02-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440457-avinger-misses-0_02-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440453\" data-ts=\"1551906717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440453-health-insurance-innovations-beats-0_21-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations beats by $0.21, beats on revenue</a></h4><ul><li>Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a>): Q4 Non-GAAP EPS of $0.98 <span style=\"color:green\">beats by $0.21</span>; GAAP EPS of $0.40 <span style=\"color:red\">misses by $0.18</span>.</li><li>Revenue of $131.92M (+89.8% Y/Y) <font color=\"green\">beats by $48.8M</font>.</li><li>Shares <font color=\"green\">+12.5%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17436012-health-insurance-innovations-inc-reports-strong-fourth-quarter-fiscal-2018-results-expands\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440453\" data-linked=\"Health Insurance Innovations beats by $0.21, beats on revenue\" data-tweet=\"$HIIQ - Health Insurance Innovations beats by $0.21, beats on revenue https://seekingalpha.com/news/3440453-health-insurance-innovations-beats-0_21-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440453-health-insurance-innovations-beats-0_21-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440452\" data-ts=\"1551906707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEO\" target=\"_blank\">AEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440452-american-eagle-outfittersminus-2-after-light-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Eagle Outfitters -2% after light profit guidance</a></h4><ul> <li>American Eagle Outfitters (NYSE:<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>) reports comparable sales increased 6% in <a href=\"https://seekingalpha.com/pr/17435999-aeo-reports-record-fourth-quarter-annual-revenue-fourth-quarter-eps-0_43-annual-eps-1_47-plus\" target=\"_blank\">Q4</a> to follow on last year's +8% mark.</li><li>The American Eagle brand saw a 3% gain in comparable sales, while comparable sales were up 23% for the Aerie brand.</li>  <li>AEO's gross margin rate was flat compared to a year ago at 34.6% as lower markdowns were offset by higher distribution and compensation expenses.</li> <li>The retailer ended the quarter with an inventory position of $424M (+7% Y/Y).</li> <li>Looking ahead, American Eagle expects Q1 EPS of $0.19 to $0.21 vs. $0.24 consensus.</li> <li>Shares of AEO are <font color=\"red\">down 2.15%</font> AH to $20.89.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440435-american-eagle-outfitters-beats-0_02-misses-revenue\" target=\"_blank\">American Eagle Outfitters beats by $0.02, misses on revenue</a> (March 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440452\" data-linked=\"American Eagle Outfitters -2% after light profit guidance\" data-tweet=\"$AEO - American Eagle Outfitters -2% after light profit guidance https://seekingalpha.com/news/3440452-american-eagle-outfittersminus-2-after-light-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3440452-american-eagle-outfittersminus-2-after-light-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440448\" data-ts=\"1551906628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440448-epizyme-launches-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme launches equity offering</a></h4><ul><li>Epizyme (NASDAQ:<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a>) <a href=\"https://seekingalpha.com/pr/17436006-epizyme-announces-proposed-concurrent-public-offerings-common-stock-series-preferred-stock\" target=\"_blank\">initiates </a>separate but concurrent public offerings of common stock and Series A convertible preferred stock. Prices, volumes and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440448\" data-linked=\"Epizyme launches equity offering\" data-tweet=\"$EPZM - Epizyme launches equity offering https://seekingalpha.com/news/3440448-epizyme-launches-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3440448-epizyme-launches-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440444\" data-ts=\"1551906536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASRT\" target=\"_blank\">ASRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440444-assertio-therapeutics-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Assertio Therapeutics beats by $0.10, beats on revenue</a></h4><ul><li>Assertio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics Inc'>ASRT</a>): Q4 Non-GAAP EPS of $0.30 <span style=\"color:green\">beats by $0.10</span>; GAAP EPS of -$0.38 <span style=\"color:red\">misses by $0.08</span>.</li><li>Revenue of $62.8M <font color=\"green\">beats by $1.17M</font>.</li><li>Shares <font color=\"green\">+6.3%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17436028-assertio-therapeutics-announces-fourth-quarter-full-year-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440444\" data-linked=\"Assertio Therapeutics beats by $0.10, beats on revenue\" data-tweet=\"$ASRT - Assertio Therapeutics beats by $0.10, beats on revenue https://seekingalpha.com/news/3440444-assertio-therapeutics-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440444-assertio-therapeutics-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440429\" data-ts=\"1551906305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APLS\" target=\"_blank\">APLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440429-apellis-readies-75m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apellis readies $75M equity offering</a></h4><ul><li>Apellis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a>) <a href=\"https://seekingalpha.com/pr/17436004-apellis-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a $75M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440429\" data-linked=\"Apellis readies $75M equity offering\" data-tweet=\"$APLS - Apellis readies $75M equity offering https://seekingalpha.com/news/3440429-apellis-readies-75m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3440429-apellis-readies-75m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440425\" data-ts=\"1551906142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440425-fox-doj-decision-on-t-mobile-sprint-month-away\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox: DOJ decision on T-Mobile/Sprint a month or more away</a></h4><ul>   <li>T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color=\"red\">-0.9%</font>) has the White House on its side in a $26B merger with Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color=\"red\">-2.2%</font>), Fox Business says, but a decision on the deal from the Justice Dept. is still at least a month away.</li>    <li>The No. 3 carrier has \"White House econ/nat security advisers\" <a href=\"https://twitter.com/CGasparino/status/1103395020688838656\" target=\"_blank\">OK with the deal</a> in order to compete with China in 5G, Charlie Gasparino tweets, but the DOJ is still concerned about the impact of a horizontal merger in a four-carrier market.</li>    <li>The FCC is still reviewing the merger as well, with a mandate not only to enforce competition but ensure the deal is in the public interest.</li>    <li>The House Judiciary Committee is <a href=\"https://seekingalpha.com/news/3440287-house-judiciary-sets-hearing-t-mobile-sprint-merger\" target=\"_blank\">taking up concerns about the deal</a> next Tuesday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440425\" data-linked=\"Fox: DOJ decision on T-Mobile/Sprint a month or more away\" data-tweet=\"$TMUS $S - Fox: DOJ decision on T-Mobile/Sprint a month or more away https://seekingalpha.com/news/3440425-fox-doj-decision-on-t-mobile-sprint-month-away?source=tweet\" data-url=\"https://seekingalpha.com/news/3440425-fox-doj-decision-on-t-mobile-sprint-month-away\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440421\" data-ts=\"1551905279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGHEF\" target=\"_blank\">PGHEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440421-pengrowth-energy-weighs-sale-after-canadian-crude-collapse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pengrowth Energy weighs sale after Canadian crude collapse</a></h4><ul><li>Pengrowth Energy (<a href='https://seekingalpha.com/symbol/PGHEF' title='PENGROWTH ENERGY CORP'>OTCQX:PGHEF</a> <font color='red'>-6.6%</font>) says it is <a href=\"https://www.bloomberg.com/news/articles/2019-03-06/oil-driller-weighs-selling-itself-after-canadian-crude-collapse\" target=\"_blank\">considering a sale</a>, merger or other business combination as part of a <a href=\"https://seekingalpha.com/pr/17434936-pengrowth-announces-fourth-quarter-2018-results-provides-reserves-update-launches-strategic\" target=\"_blank\">strategic review</a>, as the Canadian oil driller looks for ways to strengthen its balance sheet and address upcoming debt maturities.</li><li>Canadian crude\u2019s growing discount during Q4 to the U.S. benchmark \"created an extremely cautious atmosphere in the financial markets,\" CEO Pete Sametz says, and the subsequent recovery in prices \"is expected to be constructive for our [Q1] results and refinancing and strategic initiatives.\"</li><li>Pengrowth may have picked the wrong time to explore a sale, as this is \"one of the more challenging environments for such a process, with no certainty on any given outcome,\" says CIBC World Markets analyst Jamie Kubik.</li><li>The company also says it is in talks to extend the maturity on its $330M revolver due March 31.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440421\" data-linked=\"Pengrowth Energy weighs sale after Canadian crude collapse\" data-tweet=\"$PGHEF - Pengrowth Energy weighs sale after Canadian crude collapse https://seekingalpha.com/news/3440421-pengrowth-energy-weighs-sale-after-canadian-crude-collapse?source=tweet\" data-url=\"https://seekingalpha.com/news/3440421-pengrowth-energy-weighs-sale-after-canadian-crude-collapse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440418\" data-ts=\"1551904063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440418-barnes-noble-drops-lower-on-amazon-bookstore-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble drops lower on Amazon bookstore report</a></h4><ul><li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) is <font color=\"red\">down 9.05%</font> on a Wall Street Journal report indicating that Amazon plans to add more physical bookstores in the U.S.</li><li>Shares of BKS were lower on the day even before the story on the e-commerce juggernaut was published.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440409-amazon-closing-u-s-pop-ups-wsj\" target=\"_blank\">Amazon closing all U.S. pop-ups - WSJ</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440418\" data-linked=\"Barnes &amp; Noble drops lower on Amazon bookstore report\" data-tweet=\"$BKS - Barnes &amp; Noble drops lower on Amazon bookstore report https://seekingalpha.com/news/3440418-barnes-noble-drops-lower-on-amazon-bookstore-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3440418-barnes-noble-drops-lower-on-amazon-bookstore-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440416\" data-ts=\"1551903949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JKS\" target=\"_blank\">JKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440416-jinkosolar-refutes-patent-infringement-allegations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JinkoSolar refutes patent infringement allegations</a></h4><ul><li>JinkoSolar (<a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-10.2%</font>) <a href=\"https://seekingalpha.com/pr/17435298-jinkosolar-refutes-allegations-made-hanwa-q-cells\" target=\"_blank\">refutes allegations</a> by Korean rival Hanwha Q Cells that  it infringed certain patents, saying the complaints are without technical or legal merit.</li><li>Hanwha Q Cells said yesterday it <a href=\"https://www.solarpowerworldonline.com/2019/03/hanwha-sues-jinkosolar-longi-solar-and-rec-group-for-patent-infringement-on-solar-cell-technology/\" target=\"_blank\">filed a complaint</a> with the U.S. International Trade Commission against JKS and two privately held companies over the unlawful import and sale of patent-infringing  photovoltaic cells and modules.</li><li>The complaint alleges JKS has unlawfully used Hanwha's patented passivation technology into their solar cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440416\" data-linked=\"JinkoSolar refutes patent infringement allegations\" data-tweet=\"$JKS - JinkoSolar refutes patent infringement allegations https://seekingalpha.com/news/3440416-jinkosolar-refutes-patent-infringement-allegations?source=tweet\" data-url=\"https://seekingalpha.com/news/3440416-jinkosolar-refutes-patent-infringement-allegations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440400\" data-ts=\"1551901817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMC\" target=\"_blank\">VMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440400-vulcan-materials-added-to-conviction-buy-list-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vulcan Materials added to Conviction Buy List at Goldman</a></h4><ul><li>Vulcan Materials (<a href='https://seekingalpha.com/symbol/VMC' title='Vulcan Materials Company'>VMC</a> <font color='green'>+1.6%</font>) is higher after Goldman Sachs <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Upgrades+Vulcan+Materials+Company+%28VMC%29+to+Conviction+Buy/15223405.html\" target=\"_blank\">adds the stock to its Conviction Buy List</a> with a $140 price target, citing valuation and reduced expectations following several years of negative estimate revisions to manageable levels.</li><li>Goldman analyst Jerry Revich says he sees an inflection in pricing and infrastructure investment, and believes U.S. Department of Transportation budgets are up 17% in VMC's footprint in 2019 from 2017.</li><li>Revich looks for the industry to reclaim margin pressure from higher raw material costs over the course of last year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440400\" data-linked=\"Vulcan Materials added to Conviction Buy List at Goldman\" data-tweet=\"$VMC - Vulcan Materials added to Conviction Buy List at Goldman https://seekingalpha.com/news/3440400-vulcan-materials-added-to-conviction-buy-list-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3440400-vulcan-materials-added-to-conviction-buy-list-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440399\" data-ts=\"1551901094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYB\" target=\"_blank\">LYB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440399-lyondellbasellplus-6-after-goldman-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LyondellBasell +6% after Goldman upgrades to Buy</a></h4><ul><li>LyondellBasell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color='green'>+6.2%</font>) stands atop today's S&amp;P 500 leaderboard after Goldman Sachs <a href=\"https://thefly.com/thestreet/realmoney/index.php/LYBid2874888/LYB-LyondellBasell-upgraded-to-Buy-from-Neutral-at-Goldman-Sachs\" target=\"_blank\">upgrades shares to Buy</a> from Neutral and raises its price target to $125 from $104.</li><li>With the potential for the ethylene chain to establish a new trough in the coming quarters, Goldman's Robert Koort thinks investors will reassess the cyclical parameters for ethylene stocks and conclude that the new trough looks a lot like prior mid-cycle levels, which should drive valuations \"substantially higher.\"</li><li>Koort says several years have passed since the ethylene chain peaked, reflecting new capacity entering the marketplace and the decline from prior elevated oil prices that had supported peak product pricing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440399\" data-linked=\"LyondellBasell +6% after Goldman upgrades to Buy\" data-tweet=\"$LYB - LyondellBasell +6% after Goldman upgrades to Buy https://seekingalpha.com/news/3440399-lyondellbasellplus-6-after-goldman-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3440399-lyondellbasellplus-6-after-goldman-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440391\" data-ts=\"1551900377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440391-meet-ceo-blames-plunge-on-guidance-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meet CEO blames plunge on guidance expectations</a></h4><ul><li>The Meet Group (<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a> <font color='red'>-11.4%</font>) CEO Geoff Cook blames the post-earnings plunge on investors \"looking for a stronger guide.\"</li><li>Cook says the company \"saw a vision to launch our video product\" in the newly acquired Growlr app and says Meet is \"a very disciplined acquirer.\"</li><li>Source: Bloomberg First Word.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440225-meet-group-beats-q4-acquires-growlr\" target=\"_blank\">Meet Group beats Q4, acquires Growlr</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440391\" data-linked=\"Meet CEO blames plunge on guidance expectations\" data-tweet=\"$MEET - Meet CEO blames plunge on guidance expectations https://seekingalpha.com/news/3440391-meet-ceo-blames-plunge-on-guidance-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3440391-meet-ceo-blames-plunge-on-guidance-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440390\" data-ts=\"1551900192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440390-geminus-12-in-two-days-following-culps-cash-flow-revelation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE -12% in two days following Culp&#39;s cash flow revelation</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color=\"red\">-7.6%</font>) is mired in its <a href=\"https://finance.yahoo.com/news/ge-apos-6-price-target-132651517.html\" target=\"_blank\">worst two-day slump since November</a> following <a href=\"https://seekingalpha.com/news/3439920-ges-culp-sees-negative-cash-flow-2019-power-unit-struggles\" target=\"_blank\">yesterday's revelation</a> that its industrial businesses will post negative cash flow this year and today's analyst reaction.</li><li>CEO Larry Culp's efforts not to \"sugarcoat\" the \"multiyear turnaround\" in the company's power business prompted J.P. Morgan's Stephen Tusa to say his Wall Street-low $6 price target <a href=\"https://seekingalpha.com/news/3440196-tusa-ge-6-pt-generous-given-latest-news\" target=\"_blank\">might be too generous</a>.</li><li>\"We believe this is a broken business that is running out of backlog needed to feed an installed base that is now declining,\" Tusa said about the power division.</li><li>\"The cash bleed in 2019 is going to be big, very big,\" says Melius Research analyst Scott Davis. \"It is clear that a very big restructuring announcement is coming and the money to do it will be large. There is no easy way out of this mess.\"</li><li>GE shares have closed below their 200-day moving average for <a href=\"https://www.marketwatch.com/story/ge-stock-dives-as-negative-cash-flow-outlook-wipes-out-gains-from-biopharma-deal-2019-03-06\" target=\"_blank\">533 straight sessions</a>, the longest such stretch since FactSet data is available going back to January 1972, but have held above the 50-day MA since Jan. 4, 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440390\" data-linked=\"GE -12% in two days following Culp&#39;s cash flow revelation\" data-tweet=\"$GE - GE -12% in two days following Culp&#39;s cash flow revelation https://seekingalpha.com/news/3440390-geminus-12-in-two-days-following-culps-cash-flow-revelation?source=tweet\" data-url=\"https://seekingalpha.com/news/3440390-geminus-12-in-two-days-following-culps-cash-flow-revelation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440389\" data-ts=\"1551899936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESTC\" target=\"_blank\">ESTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440389-elasticminus-3-lock-up-period-expires\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elastic -3% as lock-up period expires</a></h4><ul><li>Elastic (NYSE:<a href='https://seekingalpha.com/symbol/ESTC' title='Elastic'>ESTC</a>) <font color=\"red\">drops 3%</font> as its post-IPO lock-up period expires.</li><li>A quarter of the shares subject to lock-up agreements became available today.</li><li>In its IPO prospectus, Elastic said the lock-up period would cover the traditional 180 days, which would make for an April expiration. But there were conditions that would accelerate the process.</li><li>Last week, Elastic <a href=\"https://www.businesswire.com/news/home/20190227005919/en/Elastic-N.V.-Reports-Strong-Quarter-Fiscal-2019\" target=\"_blank\">said</a> 25% of the shares would become available if Monday's closing was at least 33% higher than the $36 IPO price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440389\" data-linked=\"Elastic -3% as lock-up period expires\" data-tweet=\"$ESTC - Elastic -3% as lock-up period expires https://seekingalpha.com/news/3440389-elasticminus-3-lock-up-period-expires?source=tweet\" data-url=\"https://seekingalpha.com/news/3440389-elasticminus-3-lock-up-period-expires\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440372\" data-ts=\"1551898763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440372-lyondellbasell-industries-and-torchlight-energy-resources-among-energy-materials-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LyondellBasell Industries and Torchlight Energy Resources among Energy/Materials gainers; Renewable Energy and Pioneer Energy Services among losers</a></h4><ul><li><b>Gainers: </b>LyondellBasell Industries (NYSE:<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a>) <font color=\"green\">+7%</font>. Torchlight Energy Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Renewable Energy Group (NASDAQ:<a href='https://seekingalpha.com/symbol/REGI' title='Renewable Energy Group, Inc'>REGI</a>) <font color=\"red\">-12%</font>. Pioneer Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a>) <font color=\"red\">-10%</font>. Independence Contract Drilling (NYSE:<a href='https://seekingalpha.com/symbol/ICD' title='Independence Contract Drilling'>ICD</a>) <font color=\"red\">-9%</font>. Bristow Group (NYSE:<a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a>) <font color=\"red\">-9%</font>. ION Geophysical (NYSE:<a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440372\" data-linked=\"LyondellBasell Industries and Torchlight Energy Resources among Energy/Materials gainers; Renewable Energy and Pioneer Energy Services among losers\" data-tweet=\"$LYB $TRCH $REGI - LyondellBasell Industries and Torchlight Energy Resources among Energy/Materials gainers; Renewable Energy and Pioneer Energy Services among losers https://seekingalpha.com/news/3440372-lyondellbasell-industries-and-torchlight-energy-resources-among-energy-materials-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440372-lyondellbasell-industries-and-torchlight-energy-resources-among-energy-materials-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440367\" data-ts=\"1551897308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEO\" target=\"_blank\">AEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440367-american-eagle-outfittersplus-4-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Eagle Outfitters +4% ahead of earnings</a></h4><ul><li>Shares of American Eagle Outfitters (<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color='green'>+4%</font>) are tracking higher after mall peer Abercrombie &amp; Fitch showed <a href=\"https://seekingalpha.com/news/3440222-abercrombie-and-fitch-plus-9-percent-sales-momentum\" target=\"_blank\">sales momentum</a> in Q4.</li><li>American Eagle Outfitters is due to report earnings of its own today after the closing bell.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440367\" data-linked=\"American Eagle Outfitters +4% ahead of earnings\" data-tweet=\"$AEO - American Eagle Outfitters +4% ahead of earnings https://seekingalpha.com/news/3440367-american-eagle-outfittersplus-4-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3440367-american-eagle-outfittersplus-4-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440366\" data-ts=\"1551897210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440366-technology-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology movers and shakers</a></h4><ul><li><strong>Gainers: </strong>Renren (NYSE:<a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a>) <font color=\"green\">+35%</font>. Zayo Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) <font color=\"green\">+11%</font>. GreenSky (NASDAQ:<a href='https://seekingalpha.com/symbol/GSKY' title='GreenSky'>GSKY</a>) <font color=\"green\">+8%</font>. China TechFaith Wireless Communication Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/CNTF' title='China TechFaith Wireless Communication Technology Limited'>CNTF</a>) <font color=\"green\">+7%</font>. Uxin Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a>) <font color=\"green\">+7%</font>.</li> <li><strong>Losers: </strong>The9 Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-21%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao'>QTT</a>) <font color=\"red\">-19%</font>. The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) <font color=\"red\">-15%</font>. Aurora Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile'>JG</a>) <font color=\"red\">-12%</font>. JMU (NASDAQ:<a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a>) <font color=\"red\">-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440366\" data-linked=\"Technology movers and shakers\" data-tweet=\"$RENN $ZAYO $GSKY - Technology movers and shakers https://seekingalpha.com/news/3440366-technology-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440366-technology-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440360\" data-ts=\"1551895518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440360-microcaps-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+180%</font>. Renren (NYSE:<a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a>) <font color=\"green\">+47%</font>. Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics Inc'>SEEL</a>) <font color=\"green\">+28%</font>. Abercrombie &amp; Fitch (NYSE:<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a>) <font color=\"green\">+24%</font>. Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) <font color=\"green\">+24%</font>. OHR Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/OHRP' title='Ohr Pharmaceutical, Inc.'>OHRP</a>) <font color=\"green\">+23%</font>. Proteon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTO' title='Proteon Therapeutics'>PRTO</a>) <font color=\"green\">+15%</font>. AeroVironment (NASDAQ:<a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a>) <font color=\"green\">+15%</font>. The Stars Group (NASDAQ:<a href='https://seekingalpha.com/symbol/TSG' title='The Stars Group Inc.'>TSG</a>) <font color=\"green\">+14%</font>. Zayo Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) <font color=\"green\">+11%</font>.</li><li><strong>Losers: </strong>The9 Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-21%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a>) <font color=\"red\">-20%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao'>QTT</a>) <font color=\"red\">-19%</font>. InnerWorkings (NASDAQ:<a href='https://seekingalpha.com/symbol/INWK' title='InnerWorkings, Inc.'>INWK</a>) <font color=\"red\">-17%</font>. The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) <font color=\"red\">-17%</font>. Document Security Systems (NYSEMKT:<a href='https://seekingalpha.com/symbol/DSS' title='Document Security Systems, Inc'>DSS</a>) <font color=\"red\">-16%</font>. Capital Senior Living Corporation (NYSE:<a href='https://seekingalpha.com/symbol/CSU' title='Capital Senior Living Corporation'>CSU</a>) <font color=\"red\">-14%</font>. China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a>) <font color=\"red\">-14%</font>. Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a>) <font color=\"red\">-14%</font>. Sequential Brands Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440360\" data-linked=\"Microcaps dominate midday movers\" data-tweet=\"$BPTH $RENN $SEEL - Microcaps dominate midday movers https://seekingalpha.com/news/3440360-microcaps-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440360-microcaps-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440358\" data-ts=\"1551895077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OHRP\" target=\"_blank\">OHRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440358-ohr-pharma-up-23-ahead-of-merger-vote\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ohr Pharma up 23% ahead of merger vote</a></h4><ul><li>Thinly traded nano cap Ohr Pharmaceutical (<a href='https://seekingalpha.com/symbol/OHRP' title='Ohr Pharmaceutical, Inc.'>OHRP</a> <font color=\"green\">+23%</font>) bucks the sector's down day on more than 5x higher volume.</li><li>No particular news accounts for the action, but a key looming event is the shareholder vote next quarter on its <a href=\"https://seekingalpha.com/news/3420242-ohr-pharmaceutical-plus-82-percent-announcing-merger-neubase-therapeutics\" target=\"_blank\">proposed merger</a> with NeuBase Therapeutics.</li><li>On the working capital front, it had $3.1M in cash at year-end 2018 while operating expenses are running at ~$900K per quarter so a capital raise should be expected at some point.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440358\" data-linked=\"Ohr Pharma up 23% ahead of merger vote\" data-tweet=\"$OHRP $NBSE - Ohr Pharma up 23% ahead of merger vote https://seekingalpha.com/news/3440358-ohr-pharma-up-23-ahead-of-merger-vote?source=tweet\" data-url=\"https://seekingalpha.com/news/3440358-ohr-pharma-up-23-ahead-of-merger-vote\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440357\" data-ts=\"1551895033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440357-atlas-financial-holdings-only-financial-gainers-newmark-group-and-willis-towers-watson-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlas Financial Holdings the only financial gainers; Newmark Group and Willis Towers Watson among losers</a></h4><ul><li><b>Gainers:</b> Atlas Financial Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AFH' title='Atlas Financial Holdings'>AFH</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a>) <font color=\"red\">-10%</font>. Grupo Supervielle (NYSE:<a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a>) <font color=\"red\">-7%</font>. Triple-S Management (NYSE:<a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a>) <font color=\"red\">-7%</font>. Newmark Group (NASDAQ:<a href='https://seekingalpha.com/symbol/NMRK' title='Newmark Group, Inc.'>NMRK</a>) <font color=\"red\">-6%</font>. Willis Towers Watson (NASDAQ:<a href='https://seekingalpha.com/symbol/WLTW' title='Willis Towers Watson Public Limited'>WLTW</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440357\" data-linked=\"Atlas Financial Holdings the only financial gainers; Newmark Group and Willis Towers Watson among losers\" data-tweet=\"$AFH $XRF $SUPV - Atlas Financial Holdings the only financial gainers; Newmark Group and Willis Towers Watson among losers https://seekingalpha.com/news/3440357-atlas-financial-holdings-only-financial-gainers-newmark-group-and-willis-towers-watson-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3440357-atlas-financial-holdings-only-financial-gainers-newmark-group-and-willis-towers-watson-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440355\" data-ts=\"1551894233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XBI\" target=\"_blank\">XBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440355-biotechs-remain-under-pressure-on-gottlieb-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs remain under pressure on Gottlieb exit</a></h4><ul><li>Investors are avoiding biotechs in the wake of the abrupt resignation notice from FDA Commissioner Scott Gottlieb, M.D. who was a champion of more efficient and responsive agency action, although punters should expect another industry-friendly chief from the Trump administration.</li><li>Selected tickers: SPDR S&amp;P Biotech ETF (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color=\"red\">-2.9%</font>), Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-1.8%</font>), Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"red\">-3%</font>), Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color=\"red\">-2.4%</font>), Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color=\"red\">-2.4%</font>), Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color=\"red\">-4.2%</font>), Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"red\">-2%</font>), Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color=\"red\">-4.3%</font>), Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color=\"red\">-2.6%</font>), bluebird bio (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color=\"red\">-2.7%</font>), BioMarin Pharmaceutical (<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color=\"red\">-1.2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440355\" data-linked=\"Biotechs remain under pressure on Gottlieb exit\" data-tweet=\"$XBI $BIIB $AMGN - Biotechs remain under pressure on Gottlieb exit https://seekingalpha.com/news/3440355-biotechs-remain-under-pressure-on-gottlieb-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3440355-biotechs-remain-under-pressure-on-gottlieb-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440351\" data-ts=\"1551893313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLTR\" target=\"_blank\">DLTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440351-dollar-tree-family-dollar-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dollar Tree has a Family Dollar plan</a></h4><ul><li>Dollar Tree (<a href='https://seekingalpha.com/symbol/DLTR' title='Dollar Tree, Inc.'>DLTR</a> <font color='green'>+3.2%</font>) says it will close 390 Family Dollar stores this year and renovate another 1K locations.</li><li>The new renovated Family Dollar locations will sell alcohol and include a $1 Dollar Tree merchandise section, while some stores will also see their freezer cooler sections expanded.</li><li>\"We are confident we are taking the appropriate steps to reposition our Family Dollar brand for increasing profitability as business initiatives gain traction in the back half of fiscal 2019,\" says CEO Gary Philbin on the store strategy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440216-dollar-tree-plus-1_5-percent-earnings\" target=\"_blank\">Dollar Tree +1.5% after earnings</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440351\" data-linked=\"Dollar Tree has a Family Dollar plan\" data-tweet=\"$DLTR - Dollar Tree has a Family Dollar plan https://seekingalpha.com/news/3440351-dollar-tree-family-dollar-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3440351-dollar-tree-family-dollar-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440350\" data-ts=\"1551893288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440350-china-merchants-reinstates-coverage-of-state-owned-telecoms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Merchants reinstates coverage of state-owned telecoms</a></h4><ul>   <li>China Merchants Securities has reinstated coverage of the state-owned Chinese telecoms, favoring China Telecom (<a href=\"http://seekingalpha.com/symbol/CHA\" target=\"_blank\">CHA</a> <font color=\"red\">-4.3%</font>) and China Unicom (<a href=\"http://seekingalpha.com/symbol/CHU\" target=\"_blank\">CHU</a> <font color=\"red\">-2.6%</font>) over market leader China Mobile (<a href=\"http://seekingalpha.com/symbol/CHL\" target=\"_blank\">CHL</a> <font color=\"red\">-0.7%</font>).</li>    <li>The firm restarted coverage of China Telecom H shares at Buy, and set a price target of HK$5, implying 19% upside. And it's also Buy-rating China Unicom with a price target of HK$12, implying 25.4% upside.</li>    <li>As for China Mobile, it's gotten a Neutral rating from China Merchants. The firm set that price target at HK$80, implying 1.2% downside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440350\" data-linked=\"China Merchants reinstates coverage of state-owned telecoms\" data-tweet=\"$CHA $CHU $CHL - China Merchants reinstates coverage of state-owned telecoms https://seekingalpha.com/news/3440350-china-merchants-reinstates-coverage-of-state-owned-telecoms?source=tweet\" data-url=\"https://seekingalpha.com/news/3440350-china-merchants-reinstates-coverage-of-state-owned-telecoms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440348\" data-ts=\"1551892944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440348-encouraging-safety-profile-for-alnylams-givosiran-not-encouraging-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&quot;Encouraging&quot; safety profile for Alnylam&#39;s givosiran not so encouraging, shares down 3%</a></h4><ul><li>The broad market's bearish day notwithstanding, Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"red\">-3.4%</font>) is down on 40% higher volume following its <a href=\"https://seekingalpha.com/news/3440201-alnylams-givosiran-successful-late-stage-ahp-study\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial evaluating RNAi therapeutic givosiran in patients with acute hepatic porphyria.</li><li>The study met the primary efficacy endpoint but treatment-related <a href=\"https://seekingalpha.com/pr/17434892-alnylam-reports-positive-topline-results-envision-phase-3-study-givosiran-acute-hepatic\" target=\"_blank\">side effects were numerous</a>, undermining its \"encouraging\" assessment of the safety profile. Adverse events (AEs) were observed in 89.6% (n=43/48) of patients receiving givosiran, including a 20.8% (n=10/48) rate of serious AEs. The rates for placebo were 80.4% (n=37/46) and 8.7% (n=4/46), respectively.</li><li>Treatment-related adverse events (greater than 10%) in the givosiran arm included nausea, injection site reactions, chronic kidney disease and fatigue. There was one discontinuation due to an increase in the liver enzyme ALT greater than 8x the upper limit of normal (elevated ALT is a biomarker for liver stress/damage) which subsequently resolved. Significant elevations in liver transaminase of more than three times the upper limit of normal occurred in 14.6% (n=7/48) of treated patients, but all had evidence of iron overload or liver disease at baseline.</li><li>Adverse events (greater than 10% in the control group included headache, urinary tract infection, vomiting and pyrexia (high temperature).</li></ul><div class=\"tiny-share-widget\" data-id=\"3440348\" data-linked=\"&quot;Encouraging&quot; safety profile for Alnylam&#39;s givosiran not so encouraging, shares down 3%\" data-tweet=\"$ALNY - &quot;Encouraging&quot; safety profile for Alnylam&#39;s givosiran not so encouraging, shares down 3% https://seekingalpha.com/news/3440348-encouraging-safety-profile-for-alnylams-givosiran-not-encouraging-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3440348-encouraging-safety-profile-for-alnylams-givosiran-not-encouraging-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440346\" data-ts=\"1551892381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHF\" target=\"_blank\">WHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440346-whitehorse-financeplus-2_5-q4-core-nii-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WhiteHorse Finance +2.5% as Q4 core NII beats</a></h4><ul><li>WhiteHorse Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/WHF' title='WhiteHorse Finance'>WHF</a>)<font color=\"green\"> jumps 2.5%</font> after <a href=\"https://seekingalpha.com/pr/17435077-whitehorse-finance-inc-announces-fourth-quarter-full-year-2018-earnings-results\" target=\"_blank\">Q4 core net investment income </a>of 40 cents per share beats the consensus estimate of 36 cents.</li><li>Compares with 33 cents in the year-ago quarter.</li><li>NAV per share was $15.35 at Q4-end vs. $15.46 at Q3-end.</li><li>Total investments at fair value declined by $40.1M in Q4 vs. $509.6M in Q3, driven by the realization of WHF's investment in Aretec Group; total proceeds from the realization totaled $53.7M.</li><li>Weighted average effective yield on investments at the end of Q4 at 11.9% unchanged from the end of Q3.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440240-whitehorse-finance-beats-0_286-beats-total-investment-income\" target=\"_blank\">WhiteHorse Finance beats by $0.286, beats on total investment income</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440346\" data-linked=\"WhiteHorse Finance +2.5% as Q4 core NII beats\" data-tweet=\"$WHF - WhiteHorse Finance +2.5% as Q4 core NII beats https://seekingalpha.com/news/3440346-whitehorse-financeplus-2_5-q4-core-nii-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3440346-whitehorse-financeplus-2_5-q4-core-nii-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440343\" data-ts=\"1551891832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440343-china-automotive-systems-and-koss-among-consumer-gainers-nio-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Automotive Systems and Koss among consumer gainers; NIO leads the losers</a></h4><ul><li><b>Gainers: </b>Koss (NASDAQ:<a href='https://seekingalpha.com/symbol/KOSS' title='Koss Corporation'>KOSS</a>) <font color=\"green\">+13%</font>. Weyco Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WEYS' title='Weyco Group, Inc.'>WEYS</a>) <font color=\"green\">+6%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+6%</font>. Pingtan Marine Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a>) <font color=\"red\">-20%</font>. Sequential Brands Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"red\">-13%</font>. Fuling Global (NASDAQ:<a href='https://seekingalpha.com/symbol/FORK' title='Fuling Global'>FORK</a>) <font color=\"red\">-12%</font>. BIQI International Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/BIQI' title='Renmin Tianli Group, Inc.'>BIQI</a>) <font color=\"red\">-12%</font>. SORL Auto Parts (NASDAQ:<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440343\" data-linked=\"China Automotive Systems and Koss among consumer gainers; NIO leads the losers\" data-tweet=\"$KOSS $WEYS $CAAS - China Automotive Systems and Koss among consumer gainers; NIO leads the losers https://seekingalpha.com/news/3440343-china-automotive-systems-and-koss-among-consumer-gainers-nio-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440343-china-automotive-systems-and-koss-among-consumer-gainers-nio-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440341\" data-ts=\"1551891299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DF\" target=\"_blank\">DF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440341-dean-food-slumps-to-all-time-low-after-another-s-and-p-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dean Food slumps to all-time low after another S&amp;P cut</a></h4><ul><li>Shares of Dean Foods (<a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a> <font color='red'>-7.8%</font>) are crumbling after a brutal assessment by <a href=\"https://www.standardandpoors.com/en_US/web/guest/ratings/press-releases\" target=\"_blank\">S&amp;P Ratings</a> on the food and dairy company.</li><li>Mounting industry and operational issues are cited by S&amp;P, which made its second ratings cut on Dean in a month.</li><li>\"It is highly uncertain whether the company can successfully turn the business around over the next year,\" warns analyst Raina Patel.</li><li>The ratings agency sets a Negative outlook on Dean Foods and drops the credit rating to CCC+ from B-.</li><li>Dean Foods traded at an all-time low of $3.02 earlier in the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440341\" data-linked=\"Dean Food slumps to all-time low after another S&amp;P cut\" data-tweet=\"$DF - Dean Food slumps to all-time low after another S&amp;P cut https://seekingalpha.com/news/3440341-dean-food-slumps-to-all-time-low-after-another-s-and-p-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3440341-dean-food-slumps-to-all-time-low-after-another-s-and-p-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440340\" data-ts=\"1551891220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMP\" target=\"_blank\">IMMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440340-immutep-down-4-on-lead-candidate-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immutep down 4% on lead candidate data</a></h4><ul><li>Thinly traded nano cap Immutep Limited (<a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited ADR'>IMMP</a> <font color=\"red\">-4%</font>) is down on more than double normal volume, albeit on turnover of only 105K shares, in response to <a href=\"https://seekingalpha.com/pr/17435098-immutep-announces-data-ongoing-tacti-mel-phase-clinical-trial-unresectable-metastatic\" target=\"_blank\">updated Phase 1 results</a> on lead candidate eftilagimod alpha (\"efti\") (IMP321) in advanced melanoma patients. The data were presented at the World Immunotherapy Congress in San Diego.</li><li>The open-label study, called <a href=\"https://clinicaltrials.gov/ct2/show/NCT02676869?lead=immutep&amp;phase=0&amp;rank=5\" target=\"_blank\">TACTI-mel</a>, is evaluating the combination of efti and Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color=\"red\">-1.4%</font>) Keytruda (pembrolizumab) in 24 patients with unresectable or metastatic melanoma.</li><li>The overall response rate &#40;ORR&#41; in 18 subjects who received six months of the combination therapy at cycle 5 of Keytruda treatment was 33% with a disease control rate &#40;DCR&#41; (responders + stable cancer) of 66%. In a clinical study (<a href=\"https://clinicaltrials.gov/ct2/show/NCT01866319?titles=keynote-006&amp;rank=1\" target=\"_blank\">KEYNOTE-006</a>) conducted by Merck, melanoma patients receiving 10 mg/kg of Keytruda every three weeks showed an ORR of 33% and 34% for the bi-weekly regimen so the treatment effect of efti is unclear.</li><li>The ORR was 50% in patients who received the combination at day 1 of cycle 1 of Keytruda therapy for 12 months. The DCR remained 66%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440340\" data-linked=\"Immutep down 4% on lead candidate data\" data-tweet=\"$IMMP $MRK - Immutep down 4% on lead candidate data https://seekingalpha.com/news/3440340-immutep-down-4-on-lead-candidate-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3440340-immutep-down-4-on-lead-candidate-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440336\" data-ts=\"1551890637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INXN\" target=\"_blank\">INXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440336-interxionminus-7-revenue-growth-profits-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InterXion -7% as revenue growth, profits disappoint</a></h4><ul>   <li>InterXion (NYSE:<a href='https://seekingalpha.com/symbol/INXN' title='InterXion Holding N.V.'>INXN</a>) is <font color=\"red\">7% lower</font> today after its <a href=\"https://seekingalpha.com/news/3440192-interxion-holding-reports-q4-results\" target=\"_blank\">Q4 results</a> came in below low-side estimates despite double-digit revenue growth.</li>    <li>Revenues rose 13% and cost of sales increased 17%; gross profit rose 11%, to \u20ac89.7M.</li>    <li>But sharply higher income tax expense weighed on adjusted net income that fell 26%, to \u20ac7.8M.</li>    <li>Equipped space rose by 4,500 square meters to 144,800; revenue-generating space rose by 3,800 square meters to 115,000.</li>    <li>Utilization rate was 79% at year-end.</li>    <li>For 2019, it's guiding to revenues of \u20ac632M-\u20ac647M, EBITDA of \u20ac324M-\u20ac334M, and capital expenditures of \u20ac570M-\u20ac600M.</li>    <li><a href=\"https://seekingalpha.com/article/4246636-interxion-holding-n-v-2018-q4-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li>    <li><a href=\"https://seekingalpha.com/pr/17434906-interxion-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3440336\" data-linked=\"InterXion -7% as revenue growth, profits disappoint\" data-tweet=\"$INXN - InterXion -7% as revenue growth, profits disappoint https://seekingalpha.com/news/3440336-interxionminus-7-revenue-growth-profits-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3440336-interxionminus-7-revenue-growth-profits-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440335\" data-ts=\"1551890317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440335-nomura-sees-opportunities-in-macau-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura sees opportunities in Macau stocks</a></h4><ul><li>Nomura Instinet lifts its forecast on 2019 Macau gross gaming revenue growth to +1% from -3% due to a \"less dire outlook\" for VIP gaming activity than was previously in the hopper.</li><li>Analyst Harry Curtis sees an opportunity for investors in the beat-up sector on the revised forecast.</li><li>\"Our experience has been that when opinions are predominantly on one side (negative), the risk/reward is generally skewed to the other (upside),\" he advises.</li><li>Curtis thinks that if EBITDA multiples revert to historical averages, then total returns including dividends should be +36% for MGM Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>), +22% for Melco Resorts &amp; Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited ADR'>MLCO</a>) and +19% for Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3440335\" data-linked=\"Nomura sees opportunities in Macau stocks\" data-tweet=\"$MGM $MLCO $WYNN - Nomura sees opportunities in Macau stocks https://seekingalpha.com/news/3440335-nomura-sees-opportunities-in-macau-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3440335-nomura-sees-opportunities-in-macau-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440332\" data-ts=\"1551889653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440332-micronminus-4_6-on-dram-headwind-analyst-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron -4.6% on DRAM headwind analyst warning</a></h4><ul><li>Cleveland Research cuts its Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) 2019 revenue estimate to $24B from $25.5B citing DRAM price headwinds.</li><li>Cleveland attributes the headwinds to higher competition, weak end-demand, and customer inventory consumption.</li><li>The firm says current NAND trends will likely bring the industry under cash-cost in Q2 while the second half could become more balanced if output is reduced.</li><li>Micron shares are <font color=\"red\">down 4.6%</font> to $38.15. Peers Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='red'>-1%</font>) and Western Digital (<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a> <font color='red'>-3.5%</font>) are along for the ride.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440332\" data-linked=\"Micron -4.6% on DRAM headwind analyst warning\" data-tweet=\"$MU $MU $INTC - Micron -4.6% on DRAM headwind analyst warning https://seekingalpha.com/news/3440332-micronminus-4_6-on-dram-headwind-analyst-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3440332-micronminus-4_6-on-dram-headwind-analyst-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>101&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440331\" data-ts=\"1551889484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGND\" target=\"_blank\">LGND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440331-ligand-down-12-on-promacta-rights-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ligand down 12% on Promacta rights sale</a></h4><ul><li>Investors appear disappointed with Ligand Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a> <font color=\"red\">-11.6%</font>) <a href=\"https://seekingalpha.com/pr/17434364-ligand-sells-promacta-assets-royalty-827-million\" target=\"_blank\">agreement </a>to sell its rights to <a href=\"https://www.us.promacta.com/\" target=\"_blank\">Promacta </a>(eltrombopag) to Royalty Pharma for $827M in cash. The company plans to reinvest the proceeds to acquire assets with long-term revenue streams, fully funded \"shots on goal,\" technology platforms and share buybacks. The transaction should close today.</li><li>The company has updated its <strong>2019 guidance</strong> to $118M (from $224M) in revenues and non-GAAP EPS of $32.25 (from $6.05).</li><li><strong>Q1 guidance</strong>: revenues at least $38M and non-GAAP EPS of $30.00.</li><li>Since the product's launch in 2008, Ligand has earned $291M in royalties from net sales.</li><li>Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"red\">-0.2%</font>) markets the low blood platelet med globally.</li><li>Management will host a conference call today at 5:00 pm ET to discuss the deal. An Analyst Day is on tap for March 12 in NYC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440331\" data-linked=\"Ligand down 12% on Promacta rights sale\" data-tweet=\"$LGND $NVS - Ligand down 12% on Promacta rights sale https://seekingalpha.com/news/3440331-ligand-down-12-on-promacta-rights-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3440331-ligand-down-12-on-promacta-rights-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440330\" data-ts=\"1551889201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSG\" target=\"_blank\">TSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440330-relief-rally-for-stars-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Relief rally for The Stars Group</a></h4><ul><li>The Stars Group (<a href='https://seekingalpha.com/symbol/TSG' title='The Stars Group Inc.'>TSG</a> <font color=\"green\">+15.1%</font>) jumps to its highest level in more than a month after the company's Q4 results helps tamp down some investor concerns over acquisition integration pains.</li><li>Stars Group management says the international business saw strong organic growth, despite restrictions in certain markets.</li><li>Looking ahead, the company says it's currently on track to deliver the full $70M in cost synergies from the acquisition of Sky Betting &amp; Gaming within the current year alone, with potential opportunities for incremental synergies under review.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440168-stars-group-beats-0_08-beats-revenue\" target=\"_blank\">Stars Group beats by $0.08, beats on revenue</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440330\" data-linked=\"Relief rally for The Stars Group\" data-tweet=\"$TSG - Relief rally for The Stars Group https://seekingalpha.com/news/3440330-relief-rally-for-stars-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3440330-relief-rally-for-stars-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440327\" data-ts=\"1551888584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XAN\" target=\"_blank\">XAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440327-exantasplus-1_9-on-higher-dividend-view-q4-eps-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exantas +1.9% on higher dividend view, Q4 EPS beat</a></h4><ul><li>Exantas Capital (NYSE:<a href='https://seekingalpha.com/symbol/XAN' title='Exantas Capital Corp.'>XAN</a>) <font color=\"green\">rises 1.9%</font> after management says it expects<a href=\"https://seekingalpha.com/pr/17434669-exantas-capital-corp-reports-results-three-months-year-ended-december-31-2018\" target=\"_blank\"> a Q1 cash dividend</a> of 20 cents per share, up 14% from Q4's dividend.</li><li>Q4 adjusted core EPS of 24 cents beats the average analyst estimate of 21 cents; compares with a loss per share of 1 cent a year ago.</li><li>Originated $274.9M of new commercial real estate loans during the quarter vs. $229.0M in the year-ago quarter.</li><li>Book value per share of $14.02 at Dec. 31, 2018 slid from $14.23 at Sept. 30, 2018; economic book value per share of $13.54 fell from $13.72 at Q3-end.</li><li>Q4 sale, payoffs, and paydowns were $203.1M vs. $185.7M a year earlier.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440109-exantas-capital-beats-0_03-beats-revenue\" target=\"_blank\">Exantas Capital beats by $0.03, beats on revenue</a> (March 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440327\" data-linked=\"Exantas +1.9% on higher dividend view, Q4 EPS beat\" data-tweet=\"$XAN - Exantas +1.9% on higher dividend view, Q4 EPS beat https://seekingalpha.com/news/3440327-exantasplus-1_9-on-higher-dividend-view-q4-eps-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3440327-exantasplus-1_9-on-higher-dividend-view-q4-eps-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440326\" data-ts=\"1551888376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440326-22nd-century-group-and-tenax-therapeutics-among-healthcare-gainers-ligand-pharmaceuticals-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers</a></h4><ul><li><b>Gainers:</b>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+109%</font>. Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) <font color=\"green\">+49%</font>. Tenax Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a>) <font color=\"green\">+21%</font>. 22nd Century Group (NYSEMKT:<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a>) <font color=\"green\">+10%</font>. Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics Inc'>SEEL</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Endologix (NASDAQ:<a href='https://seekingalpha.com/symbol/ELGX' title='Endologix Inc'>ELGX</a>) <font color=\"red\">-11%</font>. Ligand Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a>) <font color=\"red\">-11%</font>. DBV Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a>) <font color=\"red\">-11%</font>. Quorum Health (NYSE:<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a>) <font color=\"red\">-10%</font>. Nemaura Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/NMRD' title='Nemaura Medical, Inc.'>NMRD</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440326\" data-linked=\"22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers\" data-tweet=\"$BPTH $AYTU $TENX - 22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers https://seekingalpha.com/news/3440326-22nd-century-group-and-tenax-therapeutics-among-healthcare-gainers-ligand-pharmaceuticals-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3440326-22nd-century-group-and-tenax-therapeutics-among-healthcare-gainers-ligand-pharmaceuticals-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440323\" data-ts=\"1551887896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLTH\" target=\"_blank\">DLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440323-duluth-holdingsminus-6-after-d-davidson-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Duluth Holdings -6% after D.A. Davidson cut</a></h4><ul> <li>Shares of Duluth Holdings (<a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='red'>-5.5%</font>) are in retreat after D.A. Davidson lowers the retailer to a Neutral rating from Buy on its view that there is a \"bumpy\" road ahead. The extended cold weather into March isn't seen as doing Duluth any favors.</li> <li>The firm takes its price target on Duluth down to $24 from $30.</li> <li>Duluth was down as much as 10.6% earlier in the session.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440323\" data-linked=\"Duluth Holdings -6% after D.A. Davidson cut\" data-tweet=\"$DLTH - Duluth Holdings -6% after D.A. Davidson cut https://seekingalpha.com/news/3440323-duluth-holdingsminus-6-after-d-davidson-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3440323-duluth-holdingsminus-6-after-d-davidson-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440321\" data-ts=\"1551887528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HFC\" target=\"_blank\">HFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440321-explosions-reported-hollyfrontier-kansas-refinery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Explosions reported at HollyFrontier Kansas refinery</a></h4><ul><li>HollyFrontier (<a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color=\"red\">-1.6%</font>) is lower following a report of <a href=\"https://www.kwch.com/content/news/Crews-responding-to-reports-of-two-explosions-at-El-Dorado-refinery--506761361.html\" target=\"_blank\">two explosions</a> at its 135K bbl/day El Dorado refinery in Kansas.</li><li>The Butler County dispatch says people are seeing black smoke caused by \"an incident.\"</li><li>A worker died from a fire at the same refinery in 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440321\" data-linked=\"Explosions reported at HollyFrontier Kansas refinery\" data-tweet=\"$HFC - Explosions reported at HollyFrontier Kansas refinery https://seekingalpha.com/news/3440321-explosions-reported-hollyfrontier-kansas-refinery?source=tweet\" data-url=\"https://seekingalpha.com/news/3440321-explosions-reported-hollyfrontier-kansas-refinery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440320\" data-ts=\"1551887334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGS\" target=\"_blank\">AGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440320-playagsplus-8-after-strong-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PlayAGS +8% after strong guidance</a></h4><ul> <li>PlayAGS (NYSE:<a href='https://seekingalpha.com/symbol/AGS' title='PlayAGS, Inc.'>AGS</a>) is <font color=\"green\">up 8.44%</font> after posting 25% revenue growth in Q4 and 19% EBITDA growth.</li> <li>Union Gaming says PlayAGS's 2019 adjusted EBITDA guidance of $160M to $164M vs. $150M consensus gives investors a reason to be excited. \"We think AGS could hit the higher end of its guidance either by exceeding our current unit sales forecast or if the company ramps in the Philippines faster than expected,\" writes Union Gaming analyst John DeCree.</li> <li>Union Gaming keeps a Buy rating on AGS and price target of $33.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439998-playags-misses-0_27-beats-revenue\" target=\"_blank\">PlayAGS misses by $0.27, beats on revenue</a> (March 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440320\" data-linked=\"PlayAGS +8% after strong guidance\" data-tweet=\"$AGS - PlayAGS +8% after strong guidance https://seekingalpha.com/news/3440320-playagsplus-8-after-strong-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3440320-playagsplus-8-after-strong-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440319\" data-ts=\"1551887147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440319-aytu-bio-up-44-on-zolpimist-licensing-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu Bio up 44% on ZolpiMist licensing deal</a></h4><ul><li>Thinly traded nano cap Aytu BioScience (<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a> <font color=\"green\">+43.6%</font>) is up on a whopping 44x surge in volume in response to its in-licensing <a href=\"https://seekingalpha.com/pr/17435170-aytu-bioscience-announces-zolpimis-tm-global-distribution-agreement-suda-pharmaceuticals\" target=\"_blank\">partnership</a> with SUDA Pharmaceuticals for the distribution of sleep aid ZolpiMist (zolpidem tartrate oral spray) outside of the U.S. and Canada (Sanofi markets the tablet formulation under the <a href=\"https://www.ambien.com/\" target=\"_blank\">Ambien</a> brand). The companies assumed the license from Magna Pharmaceuticals.</li><li>SUDA will lead development and sublicensing activities. Agreements with \"multinational pharmaceutical companies\" are already in place in China, Chile, Brazil and throughout Southeast Asia.</li><li>SUDA will pay Aytu a portion of each upfront and milestone payment received from sublicensees in addition to ongoing royalties from net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440319\" data-linked=\"Aytu Bio up 44% on ZolpiMist licensing deal\" data-tweet=\"$AYTU - Aytu Bio up 44% on ZolpiMist licensing deal https://seekingalpha.com/news/3440319-aytu-bio-up-44-on-zolpimist-licensing-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3440319-aytu-bio-up-44-on-zolpimist-licensing-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440316\" data-ts=\"1551886645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JILL\" target=\"_blank\">JILL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440316-j-jillplus-13-on-cleaner-leaner-look\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J. Jill +13% on &#39;cleaner, leaner&#39; look</a></h4><ul> <li>J. Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>) rips a <font color=\"green\">13.3% gain</font> after reporting comparable sales (-1.7% vs. -2.7% consensus) and a gross margin rate (63.1% vs. 62.0% consensus) ahead of expectations. Management cites its \"cleaner, leaner\" inventory management during the key holiday period.</li> <li>Looking ahead, J. Jill expects full-year EPS of $0.66 to $0.70 vs. $0.73 consensus, although the forecast includes a $0.09 to $0.10 hit from tech investment.</li> <li>J. Jill trades at its highest level since last August.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440171-j-jill-beats-0_02-revenue-line\" target=\"_blank\">J. Jill beats by $0.02,  revenue in-line</a> (March 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440316\" data-linked=\"J. Jill +13% on &#39;cleaner, leaner&#39; look\" data-tweet=\"$JILL - J. Jill +13% on &#39;cleaner, leaner&#39; look https://seekingalpha.com/news/3440316-j-jillplus-13-on-cleaner-leaner-look?source=tweet\" data-url=\"https://seekingalpha.com/news/3440316-j-jillplus-13-on-cleaner-leaner-look\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440313\" data-ts=\"1551886254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440313-crude-inventory-unexpectedly-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventory unexpectedly rise</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>+7.1</strong><strong>M</strong> barrels vs. +1.2M consensus, -8.6M last week.</li><li>Gasoline <strong>-4.2M</strong> barrels vs. -2.1M consensus, -1.9M last week.</li><li>Distillates <strong>-2.4M</strong> barrels vs. -1.4M consensus, -0.3M last week.</li><li>Futures <font color=\"red\">-1.64%</font> to $55.64.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440313\" data-linked=\"Crude inventory unexpectedly rise\" data-tweet=\"$USO $OIL $UCO - Crude inventory unexpectedly rise https://seekingalpha.com/news/3440313-crude-inventory-unexpectedly-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3440313-crude-inventory-unexpectedly-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440310\" data-ts=\"1551885830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440310-rokuplus-3_7-guggenheim-highlights-long-term-growth-raises-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku +3.7% as Guggenheim highlights long-term growth, raises target</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is <font color=\"green\">up 3.7%</font> after a boosted price target at Guggenheim, which says \"the potential growth runway is long\" for a company holding steady with a streaming leadership position.</li>    <li>The firm maintains a Buy rating and raised its target to $77 from $54, now implying 7.9% upside.</li>    <li>Roku should hold leadership in both OEM and content partners as it continues to be the source for connecting consumers with Internet video while tapping even more high-value addressable ad inventory, analyst Michael Morris says. Premium subscription rollouts (with Disney Plus and Charter Spectrum TV headed for debuts) continue building consumer value while offering low-risk incremental cash flow, he writes. (h/t Bloomberg)</li>    <li>After a fall decline, shares have more than doubled so far in 2019, <font color=\"green\">up 125%</font>, and they've still marked <font color=\"green\">gains of 83%</font> over the past year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440310\" data-linked=\"Roku +3.7% as Guggenheim highlights long-term growth, raises target\" data-tweet=\"$ROKU - Roku +3.7% as Guggenheim highlights long-term growth, raises target https://seekingalpha.com/news/3440310-rokuplus-3_7-guggenheim-highlights-long-term-growth-raises-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3440310-rokuplus-3_7-guggenheim-highlights-long-term-growth-raises-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440309\" data-ts=\"1551885679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DELL\" target=\"_blank\">DELL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440309-dell-to-offer-4b-first-lien-notes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dell to offer $4B first lien notes</a></h4><ul><li>Dell (NYSE:<a href='https://seekingalpha.com/symbol/DELL' title='Dell Technologies Inc.'>DELL</a>) <a href=\"https://seekingalpha.com/pr/17435308-dell-technologies-inc-announces-offering-4-billion-first-lien-notes\" target=\"_blank\">commences</a> a $4B private offering of first lien notes co-issued by its Dell International and EMC subsidiaries.</li><li>The company will use the proceeds and proceeds of refinancing to redeem or repay outstanding 3.48% first lien notes due 2019.</li><li>The company doesn't expect a material effect on its debt outstanding.</li><li>Dell shares are <font color=\"red\">down 2.5%</font> to $53.71.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440309\" data-linked=\"Dell to offer $4B first lien notes\" data-tweet=\"$DELL - Dell to offer $4B first lien notes https://seekingalpha.com/news/3440309-dell-to-offer-4b-first-lien-notes?source=tweet\" data-url=\"https://seekingalpha.com/news/3440309-dell-to-offer-4b-first-lien-notes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440308\" data-ts=\"1551885655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APC\" target=\"_blank\">APC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440308-colorado-drillers-slide-state-lawmakers-weigh-overhaul-of-drilling-laws\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Colorado drillers slide as state lawmakers weigh overhaul of drilling laws</a></h4><ul><li><a href=\"https://www.chron.com/business/energy/article/Colorado-Lawmakers-Weigh-Dramatic-Overhaul-of-Oil-13666719.php\" target=\"_blank\">A proposal to overhaul</a> Colorado's oil and gas drilling laws has its first hearing  today, pushing the bill one step closer to a vote by the  Democrat-controlled state legislature.</li><li>The legislation, supported by Gov. Polis, would significantly  change the way drilling is permitted and amend state laws  that have been instrumental in developing Colorado's Denver-Julesburg basin.</li><li>Major acreage holders in the region include Anadarko Petroleum (<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='red'>-0.8%</font>), Noble Energy (<a href='https://seekingalpha.com/symbol/NBL' title='Noble Energy, Inc.'>NBL</a> <font color='red'>-0.7%</font>), Extraction Oil and Gas (<a href='https://seekingalpha.com/symbol/XOG' title='Extraction Oil & Gas'>XOG</a> <font color='red'>-2.2%</font>), Bonanza Creek Energy (<a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='red'>-1.4%</font>), SRC Energy (<a href='https://seekingalpha.com/symbol/SRCI' title='SRC Energy Inc.'>SRCI</a> <font color='red'>-2%</font>), High Point Resources (<a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a> <font color='red'>-3.4%</font>) and PDC Energy (<a href='https://seekingalpha.com/symbol/PDCE' title='PDC Energy, Inc.'>PDCE</a> <font color='red'>-1.8%</font>).</li><li>Just <a href=\"https://seekingalpha.com/news/3406510-colorado-focused-oil-gas-companies-surge-election-victory\" target=\"_blank\">four months ago</a>, Colorado voters defeated a referendum that would have imposed new restrictions on drilling.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440308\" data-linked=\"Colorado drillers slide as state lawmakers weigh overhaul of drilling laws\" data-tweet=\"$APC $NBL $XOG - Colorado drillers slide as state lawmakers weigh overhaul of drilling laws https://seekingalpha.com/news/3440308-colorado-drillers-slide-state-lawmakers-weigh-overhaul-of-drilling-laws?source=tweet\" data-url=\"https://seekingalpha.com/news/3440308-colorado-drillers-slide-state-lawmakers-weigh-overhaul-of-drilling-laws\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>94&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440307\" data-ts=\"1551885419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440307-brown-formanminus-5-on-tariff-uncertainty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brown-Forman -5% on tariff uncertainty</a></h4><ul> <li>Brown-Forman (<a href='https://seekingalpha.com/symbol/BF.A' title='Brown-Forman Corporation'>BF.A</a>, <a href='https://seekingalpha.com/symbol/BF.B' title='Brown-Forman Corporation'>BF.B</a>) <font color=\"red\">sheds 4.7%</font> after a slight miss with Q4 revenue. Investors could be skittish over the company's warning on the uncertainty of near-term results due to tariff risk.</li> <li>\"We remain on track to deliver another strong year of results as cost discipline helped offset some of the large burden we are absorbing due to the retaliatory tariffs on American whiskey,\" says Brown-Forman CEO Lawson Whiting. \"The growth opportunity for our brand portfolio remains significant, and our teams around the world are executing on our long-term growth strategy,\" he adds.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440219-brown-forman-beats-0_02-misses-revenue\" target=\"_blank\">Brown-Forman beats by $0.02, misses on revenue</a> (March 6)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3440307\" data-linked=\"Brown-Forman -5% on tariff uncertainty\" data-tweet=\"$BF.A $BF.B - Brown-Forman -5% on tariff uncertainty https://seekingalpha.com/news/3440307-brown-formanminus-5-on-tariff-uncertainty?source=tweet\" data-url=\"https://seekingalpha.com/news/3440307-brown-formanminus-5-on-tariff-uncertainty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440303\" data-ts=\"1551884555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPOR\" target=\"_blank\">GPOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440303-gulfport-energy-investor-firefly-to-avoid-proxy-fight-for-now\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gulfport Energy investor Firefly to avoid proxy fight for now</a></h4><ul><li>Gulfport Energy (<a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color='red'>-3.2%</font>) receives a letter from 8.1% shareholder Firefly Value Partners, which says it is <a href=\"https://seekingalpha.com/pr/17435350-firefly-value-partners-sends-letter-gulfport-energy-corporation-board-directors\" target=\"_blank\">\"encouraged\" by the company's 2019 capital plan</a>, which \"effectively adopted the share repurchase plan that we recommended.\"</li><li>Firefly says GPOR still must do more to \"regain investor trust\" and believes \"the addition of meaningful stockholder representation to the board is the best way to ensure alignment between the board and stockholders,\" but it does not favor a \"distracting proxy fight to accomplish that end\" for now, instead recommending urgent execution of capital and operational plans and share buybacks.</li><li>The investor says GPOR also must set short-term and long-term executive compensation incentives that         are \"more closely aligned with the best interests of all stockholders,\" and abstain from equity issuances; otherwise, Firefly says the board's composition would need to change.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440303\" data-linked=\"Gulfport Energy investor Firefly to avoid proxy fight for now\" data-tweet=\"$GPOR - Gulfport Energy investor Firefly to avoid proxy fight for now https://seekingalpha.com/news/3440303-gulfport-energy-investor-firefly-to-avoid-proxy-fight-for-now?source=tweet\" data-url=\"https://seekingalpha.com/news/3440303-gulfport-energy-investor-firefly-to-avoid-proxy-fight-for-now\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440299\" data-ts=\"1551884283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMTS\" target=\"_blank\">PMTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440299-cpi-cardminus-2_1-on-worse-expected-q4-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CPI Card -2.1% on worse-than-expected Q4 loss</a></h4><ul><li>CPI Card Group (NASDAQ:<a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a>)<font color=\"red\"> sinks 2.1%</font> after<a href=\"https://seekingalpha.com/pr/17435177-cpi-card-group-inc-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\"> Q4 adjusted loss per share from continuing operations</a> of 48 cents came in worse than the average analyst estimate for a 9-cent loss.</li><li>Compares with a loss of 2 cents per share in the year-ago quarter.</li><li>Q4 adjusted net loss of $5.39M increased from a loss of $213K a year earlier.</li><li>The top line fared better with Q4 net sales rising 19% Y/Y to $68.5M from $57.5M.</li><li>Q4 adjusted EBITDA rose 53% to $5.1M from $3.3M a year earlier.</li><li>Free cash flow of $1.4M for the year; at Dec. 31, the company had cash and cash equivalents of $20.3M and a $40M revolving credit facility with $20M available for borrowing.</li><li>\"We continue to believe we have adequate cash and liquidity to support our business plans,\" says CFO John Lowe.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440254-cpi-card-group-misses-0_39-beats-revenue\" target=\"_blank\">CPI Card Group misses by $0.39, beats on revenue</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440299\" data-linked=\"CPI Card -2.1% on worse-than-expected Q4 loss\" data-tweet=\"$PMTS - CPI Card -2.1% on worse-than-expected Q4 loss https://seekingalpha.com/news/3440299-cpi-cardminus-2_1-on-worse-expected-q4-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3440299-cpi-cardminus-2_1-on-worse-expected-q4-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440298\" data-ts=\"1551884151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNDM\" target=\"_blank\">TNDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440298-tandem-down-4-on-cgm-software-bug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tandem down 4% on CGM software bug</a></h4><ul><li>Tandem Diabetes Care (<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color=\"red\">-3.8%</font>) says it will use its Tandem Device Updater, a remote software update tool, to <a href=\"https://seekingalpha.com/pr/17435471-tandem-diabetes-care-announces-plan-use-remote-software-update-tool-ongoing-clinical-trial\" target=\"_blank\">fix a glitch</a> in its Control-IQ technology software identified in the ongoing DCLP3 phase of the International Diabetes Closed Loop &#40;IDCL&#41; clinical trial.</li><li>The problem pertains to how the t:slim X2 insulin pump with Control-IQ manages continuous glucose monitoring &#40;CGM&#41; data under specific conditions which could alter the device's prediction of future blood sugar values and automated insulin delivery (the wrong dose of insulin could be delivered which could lead to hypoglycemia).</li><li>The company says bugs like this are rare, adding that it has not received any reports of adverse events related to the problem.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440298\" data-linked=\"Tandem down 4% on CGM software bug\" data-tweet=\"$TNDM - Tandem down 4% on CGM software bug https://seekingalpha.com/news/3440298-tandem-down-4-on-cgm-software-bug?source=tweet\" data-url=\"https://seekingalpha.com/news/3440298-tandem-down-4-on-cgm-software-bug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440297\" data-ts=\"1551884064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440297-oppenheimer-stays-on-sidelines-urban-outfitters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer stays on the sidelines with Urban Outfitters</a></h4><ul> <li>Oppenheimer sticks with a Perform rating on Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='green'>+2%</font>) after taking in the company's Q4 earnings report.</li> <li>\"We are optimistic that an onset of spring weather in coming weeks and tweaks to certain product offerings could bolster sales trends, but believe it better to stay on the sidelines, until clearer evidence of a shift in top-line momentum at the chain emerges,\" updates the firm.</li> <li>Oppenheimer expects valuation to support URBN shares, even as fundamentals falter somewhat in the quarter ahead.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3440297\" data-linked=\"Oppenheimer stays on the sidelines with Urban Outfitters\" data-tweet=\"$URBN - Oppenheimer stays on the sidelines with Urban Outfitters https://seekingalpha.com/news/3440297-oppenheimer-stays-on-sidelines-urban-outfitters?source=tweet\" data-url=\"https://seekingalpha.com/news/3440297-oppenheimer-stays-on-sidelines-urban-outfitters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440295\" data-ts=\"1551883765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440295-fitbit-rolls-out-four-new-wearables\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit rolls out four new wearables</a></h4><ul>   <li>Fitbit (<a href=\"http://seekingalpha.com/symbol/FIT\" target=\"_blank\">FIT</a> <font color=\"green\">+1.6%</font>) has launched <a href=\"https://seekingalpha.com/pr/17435460-fitbit-launches-four-new-wearables-making-health-fitness-accessible-affordable-consumers\" target=\"_blank\">four new wearable products</a>, including a new lower-end smartwatch and a new wearable for children.</li>    <li>The Versa Lite Edition builds on the Versa family as an \"everyday smartwatch\" with most of that product family's core features, priced at $159.95.</li>    <li>The company's Inspire and Inspire HR are new slim trackers like the Charge 3, but also at a lower price point: $69.95 and $99.95 respectively, with the Inspire HR marking the company's most affordable heart-rate tracker.</li>    <li>And the Ace 2 ($69.95) is aimed at children age 6 and up, with a protective screen bumper and swimproof design along with other features to appeal to children.</li>    <li>Fitbit also says its app is soon to receive a \"major redesign\" with new features including a \"Fitbit Focus\" section for the dashboard bringing relevent information forward for users.</li>    <li>The company's <a href=\"https://seekingalpha.com/pr/17435357-fitbit-solera-health-expand-partnership-reduce-risk-type-2-diabetes\" target=\"_blank\">expanding a partnership with Solera Health</a> to reduce the risk of type 2 diabetes, which will make the Inspire and Inspire HR available to Solera's Diabetes Prevention Program participants.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440295\" data-linked=\"Fitbit rolls out four new wearables\" data-tweet=\"$FIT - Fitbit rolls out four new wearables https://seekingalpha.com/news/3440295-fitbit-rolls-out-four-new-wearables?source=tweet\" data-url=\"https://seekingalpha.com/news/3440295-fitbit-rolls-out-four-new-wearables\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440292\" data-ts=\"1551883262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VECO\" target=\"_blank\">VECO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440292-veecominus-6-stifel-moves-to-hold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veeco -6% as Stifel moves to Hold</a></h4><ul><li>Stifel downgrades Veeco Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a>) from Buy to Hold with a $12 price target.</li><li>Last month, Veeco reported Q4 results with a revenue beat and mixed Q1 guidance that put revenue in-line with estimates but EPS below consensus.</li><li>Veeco shares are <font color=\"red\">down 6.3%</font> to $11.39.</li><li>Update with more information from the analyst note:</li><li>Analyst Patrick Ho: \"The company is in the middle of a transformation and at least in the near-term, we do not believe there are any \u2018new\u2019 catalysts that would lead us to increase estimates or raise our target price.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3440292\" data-linked=\"Veeco -6% as Stifel moves to Hold\" data-tweet=\"$VECO - Veeco -6% as Stifel moves to Hold https://seekingalpha.com/news/3440292-veecominus-6-stifel-moves-to-hold?source=tweet\" data-url=\"https://seekingalpha.com/news/3440292-veecominus-6-stifel-moves-to-hold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440289\" data-ts=\"1551883140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440289-fda-commish-exit-may-delay-cbd-approvals-seaport\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Commish exit may delay CBD approvals - Seaport</a></h4><ul><li>In a note, Seaport analyst Brett Hundley says the departure of FDA Commissioner Scott Gottlieb, M.D. adds \"more uncertainties\" to the evolution of the U.S. cannabidiol &#40;CBD&#41; and medical marijuana markets, adding that the agency's April meeting to launch the rule-making process for CBD may be delayed.</li><li>Pot stock investors do not appear to share his concerns.</li><li>Selected tickers: Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"green\">+1.9%</font>), Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color=\"green\">+1.3%</font>), Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"green\">+1.6%</font>), Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"green\">+1.9%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440289\" data-linked=\"FDA Commish exit may delay CBD approvals - Seaport\" data-tweet=\"$TLRY $CRON $CGC - FDA Commish exit may delay CBD approvals - Seaport https://seekingalpha.com/news/3440289-fda-commish-exit-may-delay-cbd-approvals-seaport?source=tweet\" data-url=\"https://seekingalpha.com/news/3440289-fda-commish-exit-may-delay-cbd-approvals-seaport\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440282\" data-ts=\"1551882307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440282-intelsatplus-4_1-in-rebound-to-tuesday-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat +4.1% in rebound to Tuesday slide</a></h4><ul>   <li>A day after a near-16% slide, Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>) is on the rebound a bit, <font color=\"green\">up 4.1%</font> premarket, with analysts stepping in to say the sell-off is overdone.</li>    <li>RBC said \"<a href=\"https://seekingalpha.com/news/3440104-rbc-buy-dip-intelsats-5g-tumble\" target=\"_blank\">ignore the noise</a> and buy the dip,\" reiterating an Outperform rating.</li>    <li>Meanwhile, Evercore says the thesis is unchanged and that decline is an \"overreaction.\"</li>    <li>And noting the valuation, Raymond James has upgraded shares to Market Perform, from Underperform.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440282\" data-linked=\"Intelsat +4.1% in rebound to Tuesday slide\" data-tweet=\"$I - Intelsat +4.1% in rebound to Tuesday slide https://seekingalpha.com/news/3440282-intelsatplus-4_1-in-rebound-to-tuesday-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3440282-intelsatplus-4_1-in-rebound-to-tuesday-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440281\" data-ts=\"1551882263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440281-galectin-files-for-rights-offering-shares-down-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galectin files for rights offering; shares down 1% premarket</a></h4><ul><li>Galectin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>) is down <font color=\"red\">1%</font> premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17435150-galectin-therapeutics-files-registration-statement-stockholder-rights-offering-common-stock\" target=\"_blank\">planned rights offering</a> of stock and warrants to current shareholders.</li><li>Current investors will receive one <a href=\"https://www.sec.gov/Archives/edgar/data/1133416/000119312519064707/d626180ds3.htm\" target=\"_blank\">non-transferable subscription right</a> per common share owned to buy one unit, consisting of 0.3 common shares and a warrant to purchase 0.75 common shares. Final pricing has yet to be determined.</li><li>The company expects to raise $50M - 70M, with Chairman Richard Uihlein <a href=\"https://www.sec.gov/Archives/edgar/data/1133416/000119312519064717/d702391dex991.htm\" target=\"_blank\">leading the way</a> with a $20M stake.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440281\" data-linked=\"Galectin files for rights offering; shares down 1% premarket\" data-tweet=\"$GALT - Galectin files for rights offering; shares down 1% premarket https://seekingalpha.com/news/3440281-galectin-files-for-rights-offering-shares-down-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3440281-galectin-files-for-rights-offering-shares-down-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440280\" data-ts=\"1551882011\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440280-xxii-idra-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XXII, IDRA among premarket gainers</a></h4><ul><li>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+55%</font> on <a href=\"https://seekingalpha.com/news/3440262-bio-path-54-percent-premarket-positive-prexigebersen-data\" target=\"_blank\">positive</a> prexigebersen data.</li><li>Abercrombie &amp; Fitch (NYSE:<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/news/3440209-abercrombie-and-fitch-beats-0_20-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+13%</font> <a href=\"https://seekingalpha.com/news/3440267-china-automotive-systems-plus-25-percent-landing-great-wall-ev-contract\" target=\"_blank\">after</a> landing Great Wall EV contract.</li><li>AeroVironment (NASDAQ:<a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a>) <font color=\"green\">+11%</font> on <a href=\"https://seekingalpha.com/news/3439993-aerovironment-beats-0_20-revenue-line\" target=\"_blank\">Q3 earnings</a>.</li><li>22nd Century (NYSEMKT:<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a>) <font color=\"green\">+10%</font>.</li><li>Zayo Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3440253-zayo-plus-10-percent-postponed-meeting-strategic-options\" target=\"_blank\">postponed</a> meeting for strategic options.</li><li>Ambarella (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3439978-ambarella-beats-0_10-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>The Stars Group (NASDAQ:<a href='https://seekingalpha.com/symbol/TSG' title='The Stars Group Inc.'>TSG</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3440168-stars-group-beats-0_08-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Infinity Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/pr/17434982-infinity-pharmaceuticals-announces-royalty-monetization-copiktra-30-million-gross-proceeds\" target=\"_blank\">royalty monetization</a> of COPIKTRA for $30M gross proceeds.</li><li>TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"green\">+8%</font>.</li><li>Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) <font color=\"green\">+8%</font> on global <a href=\"https://seekingalpha.com/pr/17435170-aytu-bioscience-announces-zolpimis-tm-global-distribution-agreement-suda-pharmaceuticals\" target=\"_blank\">distribution</a> Agreement with SUDA Pharmaceuticals.</li><li>Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics Inc'>SEEL</a>) <font color=\"green\">+7%</font>.</li><li>Idera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a>) <font color=\"green\">+6%</font>.</li><li>J.Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/news/3440171-j-jill-beats-0_02-revenue-line\" target=\"_blank\">Q4 earnings</a>.</li><li>Can-Fite BioPharma (NYSEMKT:<a href='https://seekingalpha.com/symbol/CANF' title='Can-Fite Biopharma Ltd'>CANF</a>) <font color=\"green\">+5%</font>.</li><li>Atlas Financial Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AFH' title='Atlas Financial Holdings'>AFH</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440280\" data-linked=\"XXII, IDRA among premarket gainers\" data-tweet=\"$BPTH $ANF $CAAS - XXII, IDRA among premarket gainers https://seekingalpha.com/news/3440280-xxii-idra-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440280-xxii-idra-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440279\" data-ts=\"1551882007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440279-nio-ge-and-wltw-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NIO, GE and WLTW among premarket losers</a></h4><ul><li>NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a>) <font color=\"red\">-20%</font> on <a href=\"https://seekingalpha.com/news/3440019-nio-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li><li>SELLAS Life Sciences Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SLS' title='SELLAS Life Sciences Group, Inc.'>SLS</a>) <font color=\"red\">-12%</font>.</li><li>Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao'>QTT</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3439969-qutoutiao-misses-0_03-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-11%</font>.</li><li>Cardlytics (NASDAQ:<a href='https://seekingalpha.com/symbol/CDLX' title='Cardlytics, Inc.'>CDLX</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3439979-cardlytics-beats-0_42-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a>) <font color=\"red\">-9%</font>.</li><li>Chico's FAS (NYSE:<a href='https://seekingalpha.com/symbol/CHS' title='Chico&#39;s FAS, Inc.'>CHS</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3440210-chicos-fas-beats-0_02-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Document Security Systems (NYSEMKT:<a href='https://seekingalpha.com/symbol/DSS' title='Document Security Systems, Inc'>DSS</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/pr/17433083-document-security-systems-inc-signs-exclusive-master-distributor-agreement\" target=\"_blank\">signing</a> a distributor agreement with Advanced Cyber Security.</li><li>General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>) <font color=\"red\">-7%</font> after <a href=\"https://seekingalpha.com/news/3440106-ge-s-lowered-expectations-quick-turnaround-wake-call\" target=\"_blank\">announcing</a> negative cash flow expectations in 2019.</li><li>JMU (NASDAQ:<a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a>) <font color=\"red\">-8%</font>.</li><li>Thor Industries (NYSE:<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3440174-thor-misses-0_37-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>United Natural Foods (NYSE:<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3439989-united-natural-foods-beats-0_23-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) <font color=\"red\">-5%</font> after <a href=\"https://seekingalpha.com/news/3440201-alnylams-givosiran-successful-late-stage-ahp-study\" target=\"_blank\">announcing</a> top line results from ENVISION phase 3 study of Givosiran.</li><li>China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"red\">-5%</font>.</li><li>Willis Towers Watson Public (NASDAQ:<a href='https://seekingalpha.com/symbol/WLTW' title='Willis Towers Watson Public Limited'>WLTW</a>) <font color=\"red\">-5%</font> after <a href=\"https://seekingalpha.com/news/3440175-aon-pursuing-willis-towers-watson-merger\" target=\"_blank\">merger</a> with Aon called off.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440279\" data-linked=\"NIO, GE and WLTW among premarket losers\" data-tweet=\"$NIO $SLS $QTT - NIO, GE and WLTW among premarket losers https://seekingalpha.com/news/3440279-nio-ge-and-wltw-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440279-nio-ge-and-wltw-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440276\" data-ts=\"1551881465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOGI\" target=\"_blank\">LOGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440276-logitechplus-3-on-fy20-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Logitech +3% on FY20 outlook</a></h4><ul><li>Logitech (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGI' title='Logitech International S.A.'>LOGI</a>) <font color=\"green\">gains 2.8%</font> pre-market reaffirms its FY19 outlook of 9% to 11% sales growth in constant currency and $340M to $345M in operating income.</li><li>The company announces a FY20 outlook of mid to high single-digit sales growth with $375M to $385M in operating income, an increase of 10% to 12% from the midpoint of the 2019 profitability outlook.</li><li>Raised long-term goals: Sales growth stays in the high single digits but the gross margin target raises to 36% to 40% (from 35% to 37%) and the operating margin target is now 11% to 14% (was 10% to 12%).</li><li>Logitech's analyst and investor day will be today at 10 AM ET with a webcast <a href=\"https://ir.logitech.com/home/default.aspx\" target=\"_blank\">here</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440276\" data-linked=\"Logitech +3% on FY20 outlook\" data-tweet=\"$LOGI - Logitech +3% on FY20 outlook https://seekingalpha.com/news/3440276-logitechplus-3-on-fy20-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3440276-logitechplus-3-on-fy20-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440271\" data-ts=\"1551880900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRS\" target=\"_blank\">VLRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440271-goldman-sachs-sees-huge-upside-for-volaris-aviation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs sees huge upside for Volaris Aviation</a></h4><ul> <li>Volaris Aviation (NYSE:<a href='https://seekingalpha.com/symbol/VLRS' title='Volaris Aviation'>VLRS</a>) shoots higher in early trading after the airline stock is upgraded by Goldman Sachs to a Buy rating from Neutral.</li> <li>Goldman lifts its price target on the ADRs to $13.80 from $7.40 to rep +60% upside potential.</li> <li>Shares of Volaris are <font color=\"green\">up 1.76%</font> premarket to $8.67 vs. a 52-week trading range of $4.87 to $9.11.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440271\" data-linked=\"Goldman Sachs sees huge upside for Volaris Aviation\" data-tweet=\"$VLRS - Goldman Sachs sees huge upside for Volaris Aviation https://seekingalpha.com/news/3440271-goldman-sachs-sees-huge-upside-for-volaris-aviation?source=tweet\" data-url=\"https://seekingalpha.com/news/3440271-goldman-sachs-sees-huge-upside-for-volaris-aviation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440267\" data-ts=\"1551880390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAAS\" target=\"_blank\">CAAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440267-china-automotive-systemsplus-25-after-landing-great-wall-ev-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Automotive Systems +25% after landing Great Wall EV contract</a></h4><ul> <li>China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) pops after the company <a href=\"https://seekingalpha.com/pr/17435201-china-automotive-systems-won-major-exclusive-eps-contract-great-wall-motors\" target=\"_blank\">discloses</a> that it landed a key supplier contract from Great Wall Motor Company.</li> <li>The company's EPS products will be installed in Great Wall's all-electric model ORA R150. Total shipments are expected to reach 150K units this year.</li> <li>CAAS is <font color=\"green\">up 25.12%</font> in premarket trading to $5.03 (52-week high).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440267\" data-linked=\"China Automotive Systems +25% after landing Great Wall EV contract\" data-tweet=\"$CAAS - China Automotive Systems +25% after landing Great Wall EV contract https://seekingalpha.com/news/3440267-china-automotive-systemsplus-25-after-landing-great-wall-ev-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3440267-china-automotive-systemsplus-25-after-landing-great-wall-ev-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440266\" data-ts=\"1551880316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440266-vmwareminus-3-goldman-steps-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VMware -3% as Goldman steps to sidelines</a></h4><ul><li>Goldman Sachs downgrades VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>) from Sell to Neutral saying that \"much of the potential upside\" from new products and the Amazon Web Services partnership is already priced into the current valuation.</li><li>The firm sees \"multiple expansion from current levels as unlikely.\"</li><li>PT set at $177.</li><li>VMW shares are <font color=\"red\">down 2.7%</font> pre-market to $168.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440266\" data-linked=\"VMware -3% as Goldman steps to sidelines\" data-tweet=\"$VMW - VMware -3% as Goldman steps to sidelines https://seekingalpha.com/news/3440266-vmwareminus-3-goldman-steps-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3440266-vmwareminus-3-goldman-steps-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440265\" data-ts=\"1551880105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALSN\" target=\"_blank\">ALSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440265-allison-transmission-slips-after-stifel-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allison Transmission slips after Stifel cut</a></h4><ul> <li>Shares of Allison Transmission (NYSE:<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a>) dip in early trading after Stifel lowers its rating on the supplier to Hold from Buy.</li> <li>The firm assigns a price target of $48 to Allison.</li> <li>ALSN <font color=\"red\">-1.26%</font> premarket to $47.08 vs. a 52-week trading range of $37.41 to $53.76.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440265\" data-linked=\"Allison Transmission slips after Stifel cut\" data-tweet=\"$ALSN - Allison Transmission slips after Stifel cut https://seekingalpha.com/news/3440265-allison-transmission-slips-after-stifel-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3440265-allison-transmission-slips-after-stifel-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440262\" data-ts=\"1551879623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPTH\" target=\"_blank\">BPTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440262-bio-path-up-54-premarket-on-positive-prexigebersen-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bio-Path up 54% premarket on positive prexigebersen data</a></h4><ul><li>Nano cap Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) is up <font color=\"green\">54%</font> premarket on increased volume in response to <a href=\"https://seekingalpha.com/pr/17435119-bio-path-announces-clinical-update-interim-analysis-phase-2-prexigebersen-trial-acute-myeloid\" target=\"_blank\">updated data</a> from an open-label <a href=\"https://clinicaltrials.gov/ct2/show/NCT02781883?lead=bio-path&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating prexigebersen (BP1001) plus low-dose cytarabine &#40;LDAC&#41; compared LDAC alone in newly diagnosed patients with acute myeloid leukemia &#40;AML&#41;.</li><li>The response rate improved to 65% (n=11/17) from 47% reported almost a year ago, including five complete responders. Six patients experienced stable cancer implying a disease control rate of 100% (n=17/17). The company says these data are impressive since the treatment group included a majority of secondary AML patients who typically do not respond well.</li><li>A second cohort has been added evaluating the combination of prexigebersen and decitabine in the same population of patients.</li><li>Prexigebersen [<a href=\"http://www.biopathholdings.com/content/product-pipeline/liposomal-grb-2.htm\" target=\"_blank\">Liposomal Grb-2</a> (Growth factor Receptor Bound protein-2)] suppresses the expression of Grb-2, an adaptor protein that links tyrosine kinases with their downstream signaling molecules. <a href=\"http://en.wikipedia.org/wiki/Tyrosine_kinase\" target=\"_blank\">Tyrosine kinases</a> function as \"on\" \"off\" switches in many cellular functions so interrupting their signaling may have an inhibitory effect on rapidly-growing cancer cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440262\" data-linked=\"Bio-Path up 54% premarket on positive prexigebersen data\" data-tweet=\"$BPTH - Bio-Path up 54% premarket on positive prexigebersen data https://seekingalpha.com/news/3440262-bio-path-up-54-premarket-on-positive-prexigebersen-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3440262-bio-path-up-54-premarket-on-positive-prexigebersen-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440257\" data-ts=\"1551879012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440257-rv-sector-on-watch-after-thor-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RV sector on watch after Thor warning</a></h4><ul> <li>The RV sector is on watch after quarterly earnings from Thor Industries arrived in weak. Thor management also warned on dealer rationalization issues that it expects to impact demand for the rest of its fiscal year (Thor just reported FQ2).</li> <li>In reaction to the soft RV print, Winnebago (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) is <font color=\"red\">5.21% lower</font> premarket and Camping World Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a>) is <font color=\"red\">down 3.50%</font>. Patrick Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/PATK' title='Patrick Industries, Inc.'>PATK</a>) is <font color=\"red\">off 0.85%</font>. LCI Industries (NYSE:<a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a>) and Johnson Outdoors (NASDAQ:<a href='https://seekingalpha.com/symbol/JOUT' title='Johnson Outdoors Inc.'>JOUT</a>) could follow their peers in a downward direction when they open for trading.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3440252-thor-minus-11-percent-dealer-rationalization-hits-hard\" target=\"_blank\">Thor -11% after dealer rationalization hits hard</a> (March 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440257\" data-linked=\"RV sector on watch after Thor warning\" data-tweet=\"$WGO $CWH $PATK - RV sector on watch after Thor warning https://seekingalpha.com/news/3440257-rv-sector-on-watch-after-thor-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3440257-rv-sector-on-watch-after-thor-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}